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ABSTRACT 
Mycoplasma pulmonis contains a membrane hemolysin that is believed to be involved in 
the acquisition of membrane precursors. This membrane hemolytic activity (mHL) can be 
released from cell suspensions into the supernatant during long term incubation in a serum-free 
medium. The kinetics of soluble hemolysin (sHL) release were studied by measuring the 
amount of sHL activity released as a function of time, by monitoring cell viability, and by 
measuring cell lysis to determine if cell death and membrane rupture were required for sHL 
release. After 1.5 hours of incubation, sHL activity could be detected in supernatants, but only 
about 20% of the original membrane-associated HL was recovered even after 8 hours of 
incubation at 37°C; Release correlated directly with cell lysis inferring that sHL release was due 
to degradative processes following cell death and was not a normal physiological process of the 
organism. The soluble hemolysin (sHL) remained in suspension during ultracentrifugation and 
failed to pass through a 50,000 mol. wt. cutoff filter, but it passed partially through a 100,000 
mol. wt. cutoff filter. Partial purification of the hemolytic activity (pHL) was achieved using 
gel filtration where the activity was found in the void volume of a G-200 Sephadex column. 
The hemolytic activity in pHL preparations resolved near the top of 5% native polyacrylarnide 
gels. Several lines of evidence suggested that pHL was a multimeric complex: gel filtration on 
Sephadex G-200 was not capable of resolving the activity, it was found in the void volume of 
the column; SDS-PAGE analysis of hemolytically-active pHL bands electroeluted from native 
gels revealed several protein bands, none of which were large enough to account for the gel 
filtration results; and separation of its components by isoelectric focusing or treatment with 
nonionic detergents resulted in permanent inactivation of the hemolytic activity. pHL had potent 
heat-sensitive chemotactic and chemokinetic activity for 1774.Al mouse macrophages, but it 
had no effect on the phagocytic ability of either 1774.Al or P338.Dl cells toward HTC-
conjugated E. coli. It also lacked rnitogenic activity towards C3H/He0uJ mouse splenocytes, 
but the rnitogenic activity of pHL preparations significantly increased after treatment at 70°C for 
90 min. Mabs that are directed against M. pulmonis rnitogen(s) recognized pHL proteins that 
were lost upon subsequent purification by native polyacrylarnide gel electrophoresis, 
electroelution, and ultrafiltration. There was a change in the immunoblot banding pattern 
following heat treatment. There was no apparent change in the size of the pHL complex 
following heat treatment as determined by ultrafiltration. These results suggest that M. 
pulmonis releases a complex from its membrane that has divergent biological activities towards 
immune effector cells. The hemolytic activity is not related to previously reported rnitogenic 
x 
activity, but may have macrophage chemotactic activity. In addition, a heat stable mitogenic 
activity has been identified that is different from previous reports. 
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GENERAL IN1RODUCTION 
Rationale and Hypothesis 
Mycoplasma pulmonis, the etiologic agent of murine respiratory mycoplasmosis, is one of 
the more serious infectious agents of laboratory rodents. M. pulmonis not only causes its own 
serious consequences in rodents, but also serves as an important model for human respiratory 
mycoplasma disease. Mycoplasmas are cell wall-less organisms that require membrane 
precursors for growth. A membrane-associated hemolytic activity, found in most mycoplasma 
species, has been proposed to be involved in the acquisition of membrane precursors from 
eukaryotic cells to which the organism is attached (125, 126). Previous studies have shown 
that cholesterol may serve as the red cell membrane receptor for the hemolysin (79). Hemolytic 
activity can be released into serum-free cell suspension supernatants during long term 
incubation. This mHL activity is trypsin-sensitive, requires bovine serum albumin (BSA) for 
activity, is inhibited by sterols in a stereo-specific manner, is enhanced with thiol-active 
substances, and is inhibited with monoclonal antibodies (Mabs) (77, 79). The sHL and the 
membrane-associated hemolysin (mHL) are essentially identical functionally (78). This project 
was undertaken to further characterize and define the composition of the sHL. The hypothesis 
addressed by this research was that the purified sHL of M. pulmonis is toxic to eukaryotic 
cells. In order to address this hypothesis, biochemical and immunological approaches were 
taken to partially purify the material, to define the mechanism of release, and to observe the 
effects sHL has on immune effector cells using various immunological assays. Purification of 
sHL by affinity chromatography using existing Mabs was hampered by the fact that the Mabs 
also reacted with BSA. The hypothesis was addressed by completing the following specific 
rums: 
• to characterize the kinetics of release of the mHL 
• to sufficiently purify the sHL so as not to hamper the characterization assays 
• to define the composition of the sHL 
• to characterize the sHL activity biologically and immunologically 
The purification and characterization of the sHL would add significantly to our 
understanding of the mycoplasma membrane-associated virulence factors. It could help explain 
the method of macromolecular acquisition by mycoplasmas, and the various effects 
mycoplasmas have on the immune system. This hemolytic activity may be one of the key 
elements in the proposed pathogenesis model of M. pulmonis. A timed-hemolysis assay 
combining the hemolysis assay with the measurement of colony-forming units (CFUs) aided in 
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determining when the sHL was released during incubation in serum-free buffer. An NADH-
oxidase assay was used to determine if cell-death was occurring during this process. The 
approaches taken to purify the activity involved various protein chemistry methods (HPLC, 
MALDI/mass spectrometry analysis, isoelectric focusing , protein sequencing, native-PAGE, 
SDS-PAGE, and electroelution). A combination of G200 Sephadex column chromatography, 
native-PAGE, electroelution, and SDS-PAGE analysis proved to be the most successful 
method. Radiolabeling with various radioactive metabolites helped aid in the identification of 
the composition of the sHL. Blastogenic, chemotactic, and phagocytosis assays were used to 
characterize the effects of sHL on the immune effector cells J774.Al and P388 .D 1. 
Thesis Organization 
This dissertation is organized in a standard format consisting of four chapters, a General 
Introduction with Literature Review, Materials and Methods, Results and Discussion and 
Conclusions. This thesis follows the convention of the American Society for Microbiology. 
Literature Review 
General introduction 
The genus Mycoplasma belongs to the order Mycoplasmatales of the Class M ollicutes 
which also contains three other orders, Entomoplasmatales, Acholeplasmatales, and 
Anaeroplasmatales (159) . The term mollicute will be used to refer to any member of the class 
whereas mycoplasma will be used to refer only to members of the family Mycoplasmataceae, 
genera Mycoplasma and Ureaplasma . The class Mollicutes now includes more than 150 species 
of mycoplasmas (207). Most of these species are parasitic, infecting a vast variety of hosts. 
They occur in most vertebrates, in numerous insect and other arthropods, and within and on 
the surfaces of many plants. At the beginning of this century mycoplasmas were considered to 
be viruses. Later, they were grouped with bacterial L-forms (154) . It has been hypothesized 
that all mycoplasmas arose by degenerative evolution from the Bacillus-Lactobacillus-
Streptococcus subgroup of Gram-positive sporeforming eubacteria (116). 
The advent of new culture techniques has led to the discovery of new species of 
mycoplasmas in man, insects, and plants. Along with the identification of these new species 
has been the identification of new characteristics. For example, members of the genus 
Mycoplasma are generally believed to be non-invasive pathogens which adhere to and colonize 
the epithelial lining of the respiratory and urogenital tracts. Two new species found in man, M. 
penetrans and M. fermentans (incognitus strain) (112, 113 , 204), are notable exceptions. 
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These species are capable of penetrating and surviving within animal cells. They also produce 
fulminating infections (111). 
Mycoplasmas are the smallest free-living, self-replicating forms of prokaryotes known. 
They have several unique features that distinguish them from other prokaryotes. The major 
defining characteristic of mollicutes is the lack of a cell wall which is one of the principle 
cellular and morphological structures of prokaryotes. Mycoplasmas contain the minimum 
number of organelles needed for growth and reproduction like other prokaryotes: a circular 
double-stranded DNA molecule provides genetic information, ribosomes are the workbench 
upon which cell proteins are assembled, and a single limiting plasma membrane separates the 
cytoplasm from the external environment (154). Most mycoplasmas lead a parasitic life style. 
They have a close association with eukaryotic host cells and can be described as membrane 
parasites. Because they have a limited genome size, the smallest among known self-replicating 
organisms (84 ), mycoplasmas depend on their host for the complete spectrum of amino acids, 
purines, pyrimidines, fatty acids, cholesterol, and vitamins (154). Consequently, they have a 
minimal number of structural elements, metabolic pathways, and components of the protein 
synthesizing machinery. Mycoplasmas express relatively few cell proteins ( 400-700) with a 
truncated set of tRNAs. They lack major energy-yielding systems since none of the 
mycoplasmas characterized so far possess the tricarboxylic acid cycle (154). Most energy 
requirements are met by the inefficient glycolysis pathway, but some mycoplasmas lack key 
elements, and thus must depend on even less effective energy-yielding systems. For instance, 
some mycoplasmas acquire ATP through arginine hydrolysis by the three enzyme arginine 
dihydrolase pathway ( 154 ). 
The focus of the research pres~nted here is on Mycoplasma pulmonis, the causative agent 
of respiratory tract disease and arthritis in both rats and mice (34). M. pulmonis infection in 
both rats and mice results in a chronic respiratory disease called murine respiratory 
mycoplasmosis (MRM). This disease provides an excellent model to study the pathogenesis of 
both acute and chronic mycoplasmal respiratory diseases. M. pulmonis in its own right is an 
important pathogen to study since it widely contaminates rodent colonies. Even commercially 
available SPF rats or mice are often mycoplasmal infected. 
The mechanisms of mycoplasma pathogenicity are still largely unknown (154). A full 
understanding of mycoplasma respiratory disease must take into account host defense 
mechanisms as well as mycoplasma physiology (156). One of the more perplexing problems is 
how the wall-less, fragile mycoplasmas resist the immune defense mechanisms of their host. 
Pathogenic mycoplasmas evoke essentially all the immunological responses of the host's 
defensive repertoire, but they induce nonspecific modulation of host immune responses which 
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could lead directly to immunosuppression by usurping a more focused, protective host 
response. A fundamental problem remains unresolved concerning the relationship between host 
immunity and mycoplasmal pathogenesis: is the lymphoid response in infected lungs directed 
against the mycoplasma, does an aberrant host immune response aid the mycoplasma in 
contributing to the lesions characteristic of MRM, or is the mycoplasma itself solely 
responsible for these lesions through some unknown pathogenic mechanism(s). There is 
accumulating evidence suggesting that, at least in certain mycoplasma-host interactions, 
mycoplasmal modulation of the immune response is involved not only in progression of 
disease and chronicity of infections, but also in the inflammatory, immunopathologic reactions 
of massive cell proliferation and chemotactic phenomena (84). The lymphoid proliferation seen 
in most mycoplasma respiratory diseases, the accumulation of macrophages, and the presence 
of neutrophils for long periods of time suggest that most of the lesions seen in mycoplasma 
respiratory disease are the result of a frustrated host immune defense. It is well-known that 
specific anti-mycoplasmal humoral and cellular immune responses are often only partially 
effective, thus leading to a chronic persistent infection (128). So far it is evident that the 
immune mechanisms operating during mycoplasma infections are complex and multifactorial. 
The immune mechanisms between mycoplasmas and the host immune cells depend on both the 
mycoplasma species and the infected host. The first step taken to elucidate the mycoplasma-
induced immune response is to identify and purify the specific mycoplasma epitopes involved. 
To clarify the mechanism responsible for immune modulation, further studies with purified 
mycoplasma suppressive and rnitogenic components should be pursued (84). 
The main emphasis of current mycoplasmal research can be divided into two general areas: 
the study of the mycoplasmal membrane and the quest for virulence factors . The most studied 
virulence factors have been the adhesins of mycoplasmas. The goal of the research presented 
here is to identify and partially characterize a soluble form of a membrane-bound hemolysin 
(125 , 126), another potential virulence factor. The hemolysins found in other bacteria have 
proven to be important virulence factors. Therefore, this hemolysin is believed to be associated 
with pathogenesis and could have virulence potential. In order to understand the importance of 
this Mycoplasma pulmonis hemolysin, a more comprehensive review of the recent literature 
will be addressed. The pathogenesis of MRM is well understood; the mechanisms that cause 
disease remain unknown. Thus, many studies have been performed on mycoplasma 
membranes to examine their structure and identify components that could adversely affect host 
responses to mycoplasma disease. These mycoplasma components could be responsible for the 
circumvention of innate immune responses which allow the pathogen to establish disease. One 
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of these M. pulmonis components is the hemolysin. This hemolysin has been documented to 
have some similarities to Gram-positive thiol-activated hemolysins (79). 
Disease pathogenesis of M. pulmonis 
M. pulmonis is the causative agent of a naturally occurring disease in both rats and mice 
called MRM. It has also been found to be the causative agent of a naturally occurring genital 
disease in rats. This naturally occurring genital tract disease in mice has not been reported. 
When injected intravenously into mice and rats, M. pulmonis causes arthritis. While the natural 
occurrence of both respiratory and genital mycoplasmoses seriously restricts the usefulness of 
rats and mice for other research purposes, they represent useful models for the study of human 
disease. There are morphological similarities and similar natural histories of chronic bronchitis, 
bronchiectasis, and emphysema in man (32). Thus rats and mice are useful models for study of 
the pathogenesis of chronic pulmonary inflammation (32) . The pathologic character of arthritis 
induced by either M. pulmonis or Mycoplasma arthritidis in rats and mice is also strikingly 
similar to that of rheumatoid arthritis of man (43). 
The exact relationship of genital to respiratory mycoplasmosis is unknown. Each has been 
detected in the absence of the other. Both genital disease and respiratory diseases caused by M. 
pulmonis progress slowly, are long in duration, and are sometimes clinically silent. In both 
diseases, successful colonization can result in genital and respiratory tracts that appear normal 
grossly but show extensive involvement microscopically. Pathologic diagnosis of these 
diseases is dependent upon microscopic evaluation of the entire respiratory and genital tracts. A 
noteworthy feature in both diseases is the inconsistency of the lesions produced in rats of the 
same age, from the same colony, even in animals from the same cage (81 ). 
There are several inherent characteristics of M. pulmonis that contribute to the pattern of 
genital and respiratory diseases. In order for M. pulmonis to cause both the genital and 
respiratory tract disease, it must adhere to the surface epithelial cells and form an intimate 
contact with the host cell surface. There has been no evidence that M. pulmonis penetrates into 
the submucosa. Adherence in both diseases is thought to be a generalized interaction of the 
mycoplasma membrane with the host-cell membrane rather than by a specialized attachment tip 
(33, 34, 108). In order to study the physical process of attachment of M. pulmonis to the host, 
adsorption of the mycoplasma to red blood cells has long been used as a model for 
mycoplasma attachment to or colonization of epithelial cells. Minion, et. al. (124) has 
suggested that attachment of M. pulmonis is not a simple attachment event, but is a two step 
process. This colonization results in a wide variety of cellular changes like epithelial destruction 
(cytoplasmic vacuolization, disruption of mitochondria), epithelial hyperplasia and metaplasia, 
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giant cell formation, altered tracheobronchial cellular kinetics, and altered mucus production. 
M. pulmonis can also cause ciliostasis of tracheal organ cultures. This renders the host 
incapable of clearing inflammatory exudates and explains the large accumulation of exudates in 
major airways in vivo. These effects are probably due to mycoplasma-induced alteration of 
host membranes, mycoplasma utilization of host cell components, and/or the release of toxic 
metabolic wastes such as hydrogen peroxide (7, 23 , 48). Direct damage to epithelial cells, 
however, does not explain many of the predominant lesions observed during disease (32). 
These lesions may result from the direct effects of a mycoplasmal component or be an indirect 
effect due to the development of host inflammatory and immune responses. Researchers need 
to determine if the cytopathic effect seen in vitro with M. pulmonis are the same as those seen 
in vivo. Stadtlander, et al., showed that the damage to the epithelium early after infection is due 
to the direct effects of M. pulmonis on the cells. Differences between two virulent strains of M. 
pulmonis seen in vivo were not observed in vitro suggesting that host responses (indirect 
effects) may contribute to these cytopathological events. The indirect cellular injuries that are 
caused by mycoplasmas may better explain these lesions. Since these diseases are chronic in 
nature and M. pulmonis persists for long periods of time, the prolonged accumulation of 
neutrophils and the release of their lysosomal enzymes could contribute to the severity of the 
lesions ( 109). Alternatively, the M. pulmonis induction of large amounts of hydrolytic 
enzymes from macrophages (203) could also contribute. Mycoplasma mitogenicity may be an 
important factor in disease. The release of lymphokines from nonspecific activation of 
lymphocytes could explain the lesions observed. 
In the 1970's it was shown conclusively that M. pulmonis alone could reproduce all of the 
characteristic clinical and pathological features of the natural respiratory disease MRM. 
Offspring of infected mothers acquire the organism vertically (from parent to offspring in 
utero) (30) and/or as a result of aerosol transmission in the first weeks of life (horizontally) 
(34). A slowly progressing respiratory disease is initiated and may resolve or persist for life. 
These animals then serve as reservoirs of infection, readily transmitting the organism via 
airborne transmission to cagemates or between adjacent cages (81). M. pulmonis quickly 
overcomes the mucociliary defense mechanisms in the respiratory tract of the host and attaches 
to the surface of the epithelial cells ( 108). The preferred sites of natural M. pulmonis infections 
in rats are the nasal passages and middle ears. Thus, the upper respiratory tract then serves as 
the reservoir of infection from which M. pulmonis may be transmitted to other animals or other 
tissues within the same host (e.g., the lower respiratory tract and/or the genital tract). MRM is 
a clinically silent infection (108), except for the terminal stages of disease when weight loss, 
roughened hair coat, nasal and ocular discharges, dyspnea, snuffling, and rales are seen. There 
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is little correlation between clinical signs and pathologic alterations. The principal gross lesions 
seen in MRM are acute and chronic rhinitis, otitis media (both of the upper respiratory tract), 
laryngotrachietis, bronchopneumonia, and bronchiectasis (all of the lower respiratory tract). 
The upper respiratory tract diseases can exist in the absence of lower respiratory tract disease 
(36). Ali of these lesions are characterized microscopically by lymphoid hyperplasia and 
chronic inflammation (33). In general, there are three steps that need to occur as a prerequisite 
for mycoplasmal disease. These are intimate attachment to the host cell surfaces in order to 
derive nutrients, the elicitation of an immune response that is both beneficial and detrimental to 
the host, and induction of chronic infection as a consequence of the mycoplasma's ability to 
evade or block immunological attack (32). The lymphoid hyperplasia seen in rats is 
lymphocytic in nature whereas in mice it is plasmacytic in nature. The basic pathology of MRM 
is well known, but the remaining question is the actual mechanism(s) by which M. pulmonis 
causes chronic disease. 
The lesions of MRM have been found to be enhanced by a variety of factors. Complex 
interactions between host, organism, and environment occur. There are several environmental 
factors that influence the progression and severity of respiratory disease. These include 
ammonia (NH3) (26, 110, 173) presence of sulfur dioxide (102) the administration of 
hexamethylphosphoramide (141) , and the levels of vitamins A and E (208). Another factor that 
influences MRM is microbial synergy like that seen with Pasteurella pneumotropica (24) and 
Sendai Virus (72). The age of the host (81) also has an effect on the progression of MRM. The 
last, but most critical determinant of susceptibility to MRM is heredity or genetic factors. There 
are striking differences seen among species (130, 137) and among strains of the same species. 
Unlike with MRM, very little is known about disease pathogenesis and immunogenesis of 
genital tract disease caused by M. pulmonis. Most of the research done on M. pulmonis genital 
tract disease has used a rat model since natural genital tract disease has not yet been reported in 
mice (36). Female rats acquire genital tract disease early in life and sometimes prior to coitus. 
One mode of transmission could be due to coprophagia. Females harboring mycoplasma in the 
upper respiratory passage transfer the infection to the vagina. Another possible mode of 
transmission could be via the hematogenous route because Juhr (83) has demonstrated a 
septicemic phase in respiratory disease caused by M. pulmonis. Colonization is primarily in the 
lower genital tract (the vagina and cervix). Here M. pulmonis adheres to both squamous and 
nonsquamous epithelial cells. The predominant gross lesions of the genital tract are peri-
oophoritis and salpingitis. These lesions are microscopically characterized by neutrophil 
exudates in the oviduct lumen, hyperplasia of the epithelium, and lymphoid infiltration into the 
submucosa. Uteri are usually normal upon gross examination. Occasionally seen are an 
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underdeveloped or partially resorbed fetus. The lesions of the uteri can range from mild metritis 
to marked pyometra and endometritis. Epithelial changes seen include hyperplasia, squamous 
metaplasia, and polyp formation. Genital tract disease in males is much less frequent. In 5% of 
the males bred with infected females, M. pulmonis could be isolated from the urethra, vas 
deferens, and the epididymis. Genital tract infection with M. pulmonis results in both a 
reduction in fertility and litter size. Studies of this naturally occurring genital disease in rats will 
hopefully decipher the role of human genital disease caused by U reaplasma urealyticum. 
The inability to clear the infection seems to be linked to the inability of the immune 
response to attack organisms already established on the respiratory epithelium (36). The 
lymphoid proliferation, accumulation of macrophages, and the presence of neutrophils for long 
periods of time suggest that most of the lesions seen in M. pulmonis diseases are the result of a 
frustrated host defense (32). There are several ways that mycoplasmas could evade the immune 
response. Mycoplasmas preferentially reside between the cilia on respiratory epithelial cells and 
thereby avoid the mucociliary clearance mechanism. There are also at least three general 
mechanisms by which mycoplasmas can circumvent or block the host immunological defenses: 
by delaying or preventing antigen recognition (antigenic variation), by altering immune 
regulatory mechanisms (mitogenesis), or by evasion of effector mechanisms (disguising 
themselves with host antigens or through the release of soluble antigens and the formation of 
immune complexes). Mycoplasmas lack cell walls and invoke the host's immunological 
defense mechanisms, yet they survive an extracellular existence inside the host for extended 
periods. In the face of an intense immune response M. pulmonis can survive for months and 
even years in the infected host (82). Until this unusual capacity is understood, the most 
important feature of mycoplasma pathogenicity will remain an enigma. 
The iffimune response generated against mycoplasma is a major determinant of the 
pathogenic outcome of MRM. Because of this, the interactions or effects of M. pulmonis on 
the immune system are being studied extensively. The immunopathological effects caused by 
M. pulmonis are beginning to take form. The first thing that occurs after M. pulmonis infection 
is the infiltration of mononuclear cells into the submucosa. Killed or live M. pulmonis elicit 
chemotactic responses that specifically recruit circulating lymphocytes. This property is not 
linked to polyclonal activation, although the two mechanisms may act synergistically. The next 
step is the development and expansion of the lesions. There are various hypotheses regarding 
the type of immunological response involved at this stage in disease pathogenesis such as 
delayed type hypersensitivity or polyclonal activation of lymphocytes during disease. The last 
process that occurs is the resolution of lesions and includes an inhibition of lesion development 
from subsequent challenge. It is most likely that specific immune responses to M. pulmonis are 
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responsible for this process. Specific immune responses may act by lowering the numbers of 
organisms and controlling tissue localization or by inhibiting pathogenic interactions between 
the organisms and host cells. The severity of the chronic lesions may be influenced by the level 
of specific immunity present. Several investigators have suggested that pathologic lesions 
produced in mycoplasma infected hosts are immune injuries (127), but it not yet clear what role 
is played by these interactions between mycoplasmas and host lymphocytes in either defense or 
pathogenicity ( 127). 
The hallmark of M. pulmonis -induced respiratory disease is the variable susceptibility of 
infected animals and the inconsistency of disease progression and lesions. The primary reason 
for this is the organism's variability and the complicated factors encountered in the respiratory 
and genital tracts of the infected host. The known pathogenic mechanisms are inadequate to 
explain M. pulmonis disease. In order to understand the role of host defenses in mycoplasmal 
disease, one must identify the membrane antigen(s) or protein(s) responsible for the 
interactions observed and define the mechanism(s) involved in the mycoplasma-invoked 
immune responses. Specific mycoplasmal proteins and epitopes involved in inducing and 
evading the immune response are only beginning to be understood. 
Mycoplasma membranes 
Mycoplasmas are unable to modify cholesterol and long-chain fatty acids, cannot carry out 
pinocytosis, and lack a cell wall and intracellular membranous structures. They are unique in 
that they contain only one membrane, the plasma membrane. This membrane is a single 
cholesterol-containing phospholipid bilayer which contains a variety of proteins and 
carbohydrates. Its function is to separate cytoplasmic components from the environment, 
provide shape, and prevent lysis under changing environmental conditions. Since it is the only 
membrane in the cell, the mycoplasma membrane is rich in enzymatic activities as well as in 
specific carriers for the transport of nutrients through the membrane. The plasma membrane 
contains all of the cellular lipid and, because these cells are small, a substantial fraction of the 
total cellular protein as well. 
Because of their simplistic structure, mycoplasma membranes have been used in many 
ways to study the general structure and function of membranes. species have been used 
extensively in the study of membrane structure. The ease of isolation of Acholeplasma 
membranes and the ability to introduce controlled alterations in their membrane composition 
directly contributed to development of fluid-mosiac model of membrane structure (155). One 
benefit is that mycoplasma membranes can be purified free of contamination with other 
membrane types. Since mycoplasmas are partially or totally incapable of synthesizing long-
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chain fatty acids and cholesterol, their membrane composition is dependent on the fatty acids 
derived from the growth medium. This ability to introduce controlled alterations in the fatty 
acid composition and cholesterol content of mycoplasma membranes has been utilized in 
studying the molecular organization and physical properties of biological membranes. Razin 
( 153) provides a review on the history behind the progression of mycoplasma membrane 
research. Reviews on recent mycoplasma membrane research can be also be found in Rottem 
and Kahane (168) and Maniloff (117). 
General composition 
The gross chemical composition of mycoplasma membranes is similar to those of other 
prokaryotic plasma membranes. It consists primarily of proteins (about 60-70% of the 
membrane mass) and lipid (about 20-30%) with little carbohydrate and small amounts of 
cytoplasmic contaminants (RNA and DNA) (120). Considerable quantities of Mg2+ and small 
amounts of Ca2+ are associated with mycoplasma membranes and probably play a role in the 
stabilization of the lipid bilayer and the binding of peripheral membrane proteins. Large 
variations in lipid/protein ratios can be induced by variations in culture conditions, particularly 
by changes in the type and amount of exogenous fatty acids or sterol added to the growth 
medium. 
The physical properties of mycoplasma membranes have been studied by a variety of 
physical methods: differential scanning calorimetry, differential thermal analysis, X-ray 
diffraction, EPR spectroscopy, NMR spectroscopy, light scattering, and fluorescence 
polarization. The majority of these physical studies firmly established that the bulk of 
membrane lipids in mycoplasmas constitute a lipid bilayer (fluid-mosiac model). There is a 
definite transbilayer asymmetry of the mycoplasma membrane with regard to the distribution of 
membrane phospholipids and glycolipids ( 121, 151, 167). Cholesterol was found to flip-flop 
from the outer to inner halves of the lipid bilayer thus leading to an equal distribution in the 
bilayer (19, 38). These studies are more comprehensively reviewed in Rottem and Kahane 
(168) and Maniloff (120). 
Lipids 
Mycoplasma membranes are composed of relatively few lipid species. Several unique lipids 
occur, most of which are derived from the culture medium and represent absolute nutritional 
requirements. Some are synthesized de nova (188) from fatty acids obtained from the growth 
medium. The lipid species found are as diverse as the genera and species that make up this 
class of Mollicutes. The lipid content of the membrane varies between the various species and 
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depends on the growth phase and growth medium. Lipids are located exclusively in the 
cytoplasmic membrane and constitute 25-35% of the dry weight of the membrane ( 168). 
Acholeplasma membranes differ from those of Mycoplasma species in their high content of 
glycosyldiglycerides and phosphoglycolipids. 
The major membrane lipids of mycoplasmas are carbohydrate-containing lipids (glycolipids 
and glycophospholipids), phospholipids, neutral lipids, and sterols. The major endogenous 
membrane polar lipids in most mycoplasmas are the acidic glycerophospholipids, the neutral 
glyceroglycolipids, and a wide variety of other minor lipids may be present as well. 
Glycolipids are notably absent from many mycoplasma species, but when they are present, 
specifically in A. laidlawii, they constitute a significant portion of the membrane lipid. In A. 
laidlawii, the glycolipids are predominantly monoglucosyldiglyceride, and diglucosyl-
diglyceride. These carbohydrate-containing membrane lipids are exposed on the external 
surfaces of several mycoplasma species. In most mycoplasma species, the exogenous 
phospholipids are incorporated unchanged from the growth medium. In common with most 
other prokaryotes, the principal de nova synthesized phospholipids of mycoplasmas are the 
acidic glycerophospholipids phosphatidylglycerol and diphosphatidylglycerol. Unlike most 
eucaryotes and prokaryotes, the ubiquitous aminophospholipids phosphatidylethanolamine or 
phosphatidylserine are almost completely absent from mycoplasmas. In Mycoplasma, not 
Acholeplasma, significant amounts of phosphatidylcholine and sphingomyelin, as well as free 
and esterified cholesterol from the growth medium, are incorporated into the cell membrane. 
The neutral lipids are found in small amounts in all mycoplasmas. Neutral glycolipids 
predominate in Acholeplasma species whereas the acidic phosphatides predominate in 
Mycoplasma species. Most mycoplasmas, except for acholeplasmas, are defective in their fatty 
acid biosynthesis. Th~y cannot synthesize saturated or unsaturated fatty acids, or alter the chain 
length of either. Thus, most of their fatty acids are supplied to them in their growth medium. 
Another type of lipid, a conjugated lipid, has been identified in some, but not all 
mycoplasma species. This type of lipid, called a lipoglycan, is composed of polysaccharides 
covalently attached to lipids. These lipoglycans are surface structures that are associated 
exclusively with the cytoplasmic membrane. Many studies have been done to compare these 
lipoglycans with the bacterial lipopolysaccharides (186): Lipoglycans are distinguished from 
Gram negative bacterial lipopolysaccharides in molecular structure (no lipid A backbone) and 
biological effects on mammalian cells and intact hosts. The lipoglycan identified in M. 
neurolyticum has been found to be mitogenic. Lipoglycans cannot play a role in either the 
mitogenicity or the Ia-inducing activity of either M. arthritidis or M. pulmonis, since these 
organisms have been shown to be devoid of lipoglycans. The lipoglycan of acholeplasmas has 
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toxicity for mammalian cells. High concentrations of lipoglycan results in hemolysis. The 
lipoglycans can modulate the immune response of hosts to both soluble and particulate 
antigens. Despite all of these interactions with eukaryotic cells, the exact role of lipoglycans in 
mycoplasma cells is not known. 
Cholesterol 
The members of the class Mycoplasmataceae and Serpulina hyodysenteriae (189) are the 
only prokaryotes that require cholesterol for growth. Cholesterol concentrations can reach up to 
50 mol% of the total membrane lipids in mycoplasma species, which is comparable to the 
levels found in plasma membranes of eukaryotic cells. The non-cholesterol requiring 
acholeplasma has a much lower cholesterol level (up to 10 mol%) (168). None of the 
mycoplasmas tested so far, including the non-sterol requiring species, are capable of 
cholesterol synthesis nor or do they metabolize or modify the sterol molecule. Serum 
lipoproteins (38, 62, 158, 184) are the ordinary donors of the unesterfied cholesterol 
incorporated from the growth medium. In contrast to mammalian cells, where cholesterol can 
be synthesized de novo or taken up by receptor-mediated endocytosis, mycoplasmas must 
absorb all of their cholesterol by processes which take place exclusively at the outer surface of 
the plasma membrane (168). Razin et al. (158) showed that Mycoplasma and Spiroplasma 
species incorporate phospholipids along with free and unesterfied cholesterol from the serum 
lipoproteins. Since mycoplasmas do not use endocytosis or pinocytosis to incorporate 
cholesterol, they have devised another mechanism to incorporate the cholesterol. The 
mechanism by which cholesterol is transferred from the serum lipoproteins to mycoplasma 
membranes involves a simple exchange process which does not involve the adherence or 
fusion of the particles with the membrane. No significant degradation of the lipoprotein 
molecule is seen in this process (62, 63, 184). Mycoplasmas, but not acholeplasmas, are 
thought to have protein receptors for cholesterol (63). 
Cholesterol is the major sterol found in all species of mycoplasmas, spiroplasmas, and 
ureaplasmas. Several different sterol analogues of cholesterol, however, can support 
mycoplasma growth although they provide a limited degree of functionality as a sterol 
substitute. In order to permit growth, these sterols must contain a planar nucleus, a free 
hydroxyl group at the 3~-position, an amphipathic nature, and a branched, aliphatic 
hydrocarbon side chain at least 8 carbons long. Any steroid containing an aliphatic side chain 
can be incorporated, but only planar 3-hydroxyl sterols pennit growth. These structural 
requirements for cholesterol lead to an unique orientation of cholesterol in the mycoplasma 
membrane. Its rigid ring system will be aligned parallel to the hydrocarbon chains of membrane 
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phospholipids. The phospholipid content of the membrane and their physical state influences 
the amount of cholesterol taken up (148, 149). The polar hydroxyl group anchors one end of 
the cholesterol molecule to the polar surface of the bilayer. Extension of the planar hydrocarbon 
toward the center of the bilayer exerts a condensing effect on lipids at temperatures above the 
phase transition temperature. At temperatures below the phase transition temperature, 
cholesterol will prevent the cooperative crystallization of the hydrocarbon chain (166). The 
hydrophobic interactions between cholesterol and the phospholipids act to order fatty acyl 
chains above the phase transition and disorder those below the phase transition. This causes the 
thermal phase transitions to broaden. 
By adapting M. mycoides subsp. capri to grow with minimal amounts of cholesterol (1 69), 
one of the primary mechanisms that cholesterol plays in the membrane was discovered. These 
studies provided the first solid proof that cholesterol functions as a regulator of membrane 
fluidity (152). Cholesterol has a profound effect on membrane physical properties such as 
membrane lipid ordering and permeability, condensation of membrane phospholipids, lateral 
diffusion of phospholipids, lateral phase separations, and phospholipid phase transitions. The 
incorporation of large quantities of sterol may be necessary to prevent membrane lipids from 
crystallization at their optimal growth temperatures. Thus, cholesterol creates an intermediate 
fluid state of the lipid bilayer supporting the function of key membrane enzymes such as the 
membrane-bound A TPase. Cholesterol helps to overcome the mycoplasmas ' s inability to 
control membrane fluidity by fatty acid and complex lipid biosynthesis. Besides altering the 
thermodynamic properties of lipid bilayers, cholesterol also acts to reduce the membrane 
surface area by "condensing" the phospholipid molecules and serves to alter bilayer thickness. 
This architectural/bulk function influences the membrane physical state and is one of the dual 
roles of sterols in mycoplasma membranes. The other role is regulatory in nature and is 
fulfilled by minor amounts of sterol which has no measurable effect on bulk physical 
membrane properties. Apart from the bulk function, cholesterol may act in microdomains to 
regulate specific metabolic processes (sterol synergism). Also, cholesterol may bind to specific 
membrane proteins and affect their function (12, 49). Cholesterol may have a role in potassium 
transport. What distinguishes the regulatory role of sterol from the bulk role is its structural 
specificity. The bulk role can be fulfilled by a broad spectrum of sterol structures whereas a 
small amount of cholesterol fulfills a more specialized regulatory role. Despite intensive 
investigations on sterol-phospholipid interactions in the last decade, the exact role of sterol in 
mycoplasma membranes remains elusive ( 168). 
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Proteins 
Protein is a major component of the mycoplasma membrane. The electrophoretic pattern of 
mycoplasma membrane proteins are reproducible and species-specific. The advantage of these 
electrophoretic patterns is that they are not significantly affected by variations in in vitro growth 
conditions unlike lipids. The disadvantage of these electrophoretic patterns is that some 
exogenous proteins (serum proteins from the growth media) are tightly bound to the membrane 
and may easily be confused with true membrane proteins. Metabolic radiolabeling is an 
effective way to discriminate cell proteins from exogenous contaminants in mollicutes. The 
high ratio of membrane lipid to total protein in mycoplasmas is greater than that found in other 
prokaryotes. This increases the difficulty of purifying mycoplasmal membrane proteins for 
structural and functional analysis. Many of these proteins are anchored to the mollicute 
membrane by fatty acid tails. The role of protein membrane components in mycoplasma 
pathogenicity has become one of the important issues in mycoplasma research. 
Essentially two groups of mollicute membrane proteins have been studied. The first group 
consists of adherence or antigen-variable proteins of the pathogenic species M. genitalium, M. 
hyorhinis, and M. pneumoniae. The second group consists of structural proteins and enzymes 
of A. laidlawii, Spiroplasma species, and M. capricolum. Similar to other biological membrane 
proteins, the molecular weights of the mycoplasma membrane proteins range from 15 to over 
200 kilodalton (kDa). Two-dimensional gel analysis revealed that most mollicute membrane 
proteins are acidic with pl values ranging from pH 4 to 7 (140). The majority of these proteins 
are exposed on the inner, cytoplasmic side of the membrane. Highly glycosylated membrane 
proteins appear to be absent in mycoplasmas. Instead, a significant number of the membrane 
proteins in this organism (-25) are acylated (138). 
A prominent feature of several mollicutes is the large number of membrane proteins that 
contain covalently attached fatty acyl chains. The reason for this acylation is to anchor proteins 
which may be trapped in the periplasmic space of conventional bacteria firmly to the 
membrane. These acylated proteins or lipoproteins are exposed on the cell surface and thus act 
as important cell antigens. They may be the dominant antigens of mycoplasmas. The genes for 
several lipoproteins have been cloned and sequenced (20). The function of these lipoproteins 
has not been determined, but they may serve a functional role to enhance membrane stability, 
as a system for antigen variation to evade immune surveillance, a host adaptation role or assist 
in maintaining population diversity. 
Lipoproteins, along with some unmodified integral membrane proteins, constitute the major 
components of the mycoplasmal variable antigenic systems. This is a benefit for mycoplasmas 
since their small genome size permits them to encode and express relatively few genes 
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compared to other eubacteria while providing for significant antigenic changes. Antigenic 
variation provides a possible mechanism by which mycoplasmas survive host defenses causing 
chronic disease. Phase switching of major membrane antigen genes results in a constantly 
changing surface antigenicity which is believed to provide an effective escape from rapid 
elimination by the host immune system (215). 
Many mycoplasma species display "families" of membrane proteins encoded by multiple, 
variant genes that vary both in their expression pattern (phase switching) and in their structural 
attributes (size variation). Three size-variant membrane surface lipoproteins (Vlps) of M. 
hyorhinis (216) have divergent external domains. These domains undergo size variations by 
loss or gain of repetitive intragenic coding sequences while retaining a motif with a 
characteristic negative charge. Experimental evidence exists for the occurrence of antigenic 
variation in vivo (60, 61, 198). Studies of the V-1 antigen of M. pulmonis has provided some 
the first evidence of a role in pathogenesis for variable surface proteins. The M. pulmonis V-1 
antigen has both structurally and antigenically different forms that exist among strains (210). 
DNA inversion has been discovered as a possible mechanism by which M. pulmonis alters the 
V-1 structure. There is an interchange of the two variable regions with a single conserved 
region, and this DNA inversion acts as a switch which allows only one of two different genes 
to be expressed at any given time (183). The precise function of these antigen variation systems 
is not known. Simmons et al. suggested that this yet-undefined function of V- 1 resides in the 
variable carboxy region of these proteins. The genes encoding V-1 are similar in structure to 
genes encoding other mycoplasma surface lipoproteins. 
The same lipid-modified proteins responsible for antigenic variation may also act as 
adhesins in some mycoplasmas (217). Adhesins act in concert with other mycoplasma 
membrane components in adherence to tissues (9, 85, 86, 157). The proteins involved in 
adhesion have been the main focus of mycoplasmal research since the late 1970's. Loss of 
adherence by mutation results in loss of infectivity, and reversion to the cytadhering phenotype 
results in resumption of infectivity and virulence. The best defined mycoplasma adhesins are 
the 170 and 30 kDa proteins from M. pneumoniae and the 135 kDa protein of M. genitalium 
which is closely related to Pl (9, 157). These and other proteins form an attachment tip 
organelle in these two species. Auxiliary proteins such as the high molecular weight (HMW) 
proteins of M. pneumoniae play a yet to be determined role, presumably as part of a 
cytoskeleton. This cytoskeleton appears to be involved in the organization of the adhesins and 
in the terminal tip structure of the other flask-shaped pathogenic species. Most attention has 
been given to the adhesins and cytoskeletal elements of M. pneumoniae and M. genitalium. The 
main components forming the M. pneumoniae cytoskeleton, sometimes referred to as the 
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Triton shell, have been identified and characterized. They include 30, 40, and 90 kDa proteins 
along with p65, p200, HMWl, HMW3. They are praline rich and have repeat sequences and 
other motifs characteristic of eukaryotic cytoskeletal proteins. Efforts have been made to 
localize these proteins in the membrane and to determine their interactions forming the 
cytoskeletal network (105, 146). These accessory proteins act in concert to facilitate the lateral 
movement and concentration of the adhesin molecules at the attachment tip organelle. So far, 
data indicate that the adhesins and other surface components involved in adherence are not 
directly responsible for the cytopathic effects, but their proximity to the host cell membrane 
may form a microenvironment enabling other factors to cause the cytopathic process. 
Investigators have found adhesins in other mycoplasma species including M. hyopneumoniae 
(217) and M. hominis (70). M. pirum (205) is thought to have an adhesin that shows 26% 
amino acid homology with the M. pneumoniae Pl adhesin. 
Mitogens produced by different mycoplasmas are a heterogeneous group of molecules. 
They are mainly polyclonal B-cell activators ( 47, 170). Characterization of a few of these B-
cell rnitogens showed that lipids do not play a part in their rnitogenic activity. However, 
lipoproteins have also been related to mi to genesis. M. f ermentans and M. penetrans (66) have 
lipoproteins that appear to act as B-cell mitogens. One exception is the M. arthritidis 
superantigen, MAM, which is a potent T cell activator. It has the ability to induce cytotoxic 
lymphocytes and lymphocyte proliferation depending on MHC expression. It is the most potent 
mycoplasma activator of the immune system so far characterized. MAM has been purified (8), 
cloned and sequenced ( 42). MAM varies from other bacterial superantigens because it has a 
preference for the 1-Ea chain of the MHC II. The importance of MAM is that it may provide an 
explanation as to why mycoplasmal chronic infections often appear as autoimmune reactions. 
None of these mitogens have been purified, but recently a monoclonal antibody to the M. 
pulmonis rnitogen has been reported which might facilitate its purification (104). 
In addition to the purified membrane proteins listed, many membrane-associated enzyme 
activities have been described for mollicutes: transport activities for K+ and glucose; 
phosphatase; peptidase; thioesterase; nucleases; enzymes in membrane lipid metabolism (150, 
185, 187). The peptidases and nucleases are proposed to be involved in the transport of 
nutrients of lower molecular weight such as amino acids and nucleosides supplied in the 
growth medium. Several of these enzymes need a specific lipid environment for proper 
function. Four membrane enzymes of known activity have been purified. Two of them, NADH 
oxidase and the Na++ Mg2+ -ATPase, have been purified from A. laidlawii. The ATPase and 
NADH oxidase activities are localized on the inner cytoplasmic face of the cell membrane. 
These enzymes play a key role in respiration and energy coupling. Two other membrane 
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enzymes have been purified from M. salivarium; aminopeptidase My is a membrane 
aminopeptidase, and carboxypeptidase My (218 kDa) is an arginine-specific carboxypeptidase 
present exclusively in nonfermentative mycoplasmas. 
The mollicute membrane proteins exhibit the same structural features as established for 
membrane proteins in general. Besides certain amino acid sequence similarities for a few 
membrane proteins, no obvious close relationships to the Gram positive relatives of the 
mollicutes have been found. Apart from their structural and catalytic roles, they also have a 
major share in the immunological activities of mycoplasma cells. 
Immune responses against M. pulmonis 
As a group, mycoplasmas have a wide range of immunomodulatory effects. The diverse 
and multiple effects that mycoplasmas have on the cells of the immune system include 
polyclonal activation of B cells in vivo (213) and in vitro (132) and T cells (45, 133); induction 
of expression of major histocompatibility complex class I and class II molecules (164, 195); 
macrophage activation (193); stimulation of cytotoxic or cytolytic activities of macrophages, T 
cells ( 47) and NK cells; and induction of the production of cytokines IL-1 , IL-2 ( 11 , 115), IL-
4, IL-6, interferons, TNF-a (6), and granulocyte-macrophage colony stimulating factor (GM-
CSF) (194). 
The chronic nature of MRM suggests that the host's immune response is inefficient in 
clearing M. pulmonis. The basis for this inefficiency is not understood. Differences in 
susceptibilities between strains of rats (52, 57, 58) and mice (56, 171) has been used to give 
insights into immune mechanisms operative against M. pulmonis. Ultimately, it is hoped that 
examination of how these rat and mice strains differ in their responses to M. pulmonis infection 
will identify the pathogenic mechanisms influencing mycoplasma respiratory disease 
expression (65). 
Most of the studies of the immune response against M. pulmonis have involved LEW and 
F344 rat strains which differ in their severity and progression of MRM. LEW rats suffer a 
more severe MRM with more severe upper and lower respiratory tract lesions than do F344 
rats (52). In contrast, F344 lung lesions begin to resolve after only 28 days post infection. 
Also the numbers of lung lymphocytes in F344 rats do not increase overall and only restricted 
lymphocyte classes increase during the first month of infection (58). LEW lesions continue to 
increase after 28 days post infection along with increased infiltration of all classes of 
lymphocytes throughout the course of disease (58). One explanation for this difference is that 
F344 rats and LEW rats differ in their innate abilities to respond nonspecifically (57, 176) and 
specifically ( 17 5) to immunologic stimuli. Another possible explanation is that one of these two 
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rat strains have an inadequate serum antibody response. Simecka et al., however, showed that 
infected LEW rats produce at least as much of each class of specific antibody to M. pulmonis 
as do F344 rats ( 177). Further studies showed that the level of local antibody production alone, 
like that of serum antibody, is not responsible for the low susceptibility of F344 rats to MRM 
(176) . 
Two mouse strains also differ in their susceptibility to MRM; C3H/HeN mice are 
susceptible while C57BL/6N mice are resistant to M. pulmonis infection. C3H/HeN and 
C57BL/6N mice differed in the severity of chronic MRM in the lower, but not the upper 
respiratory tract after infection with M. pulmonis (29). Both strains of mice developed the same 
classes of antibody (29). C3H/HeN have a greater increase in inflammatory cells yet they have 
poor intrapulmonary killing of M. pulmonis (53, 142). Also, C3H/HeN mice and LEW rats 
produce more total IgG following M. pulmonis infection than do the resistant C57BL/6N mice 
and F344 rats (29). Like the rat strains ( 177), serum antibody does not account for differences 
in the severity of chronic respiratory disease in different strains of mice. LEW and F344 rats 
differ in the IgG subclasses contributing to the total IgG response, unlike C3H/HeN and 
C57BL/6N mice, and disease severity in rats is probably due to differences in regulator T cell 
function ( 177). 
It is not known what innate host mechanisms are responsible for limiting the continued 
growth of organisms and thereby maintaining differences in disease severity between these 
strains of rats and mice. One possibility is that the differences in susceptibility are due to 
differences in the innate host defenses. C57BL/6N and F344 have more effective innate 
clearance mechanisms (53, 56, 142). These studies suggest that adaptive immune responses 
are ineffective in clearing the organism (29). The other possibility is that basic genetic 
differences between the two strains may predetermine recovery from MRM. In fact, receptors 
for mycoplasma attachment are under genetic control, suggesting that certain hosts are more 
susceptible to both specific and nonspecific immune stimulation (67). Lai et. al. used the 
difference in mouse strains to determine that an autosomal single dominant gene (MPr) confers 
resistance to M. pulmonis growth in the lungs (100). This gene confers resistance to early 
stages of infection before the development of significant humoral or T cell-mediated responses 
to M. pulmonis ( 100). 
Innate immunity 
Innate immunity is the first defense line mycoplasmas contact as they initiate infection. In 
the lungs, mucociliary clearance and intrapulmonary killing are the major processes responsible 
for nonspecific resistance. Alveolar macrophages are the principal mediators of intrapulmonary 
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killing of bacteria ( 178). Other components that play a part in intrapulmonary killing are 
neutrophils or polymorphonuclear leucocytes, nonspecific opsonins such as fibronectin, serum 
components, and complement, and unidentified fluid factors ( 178). The chronicity of 
mycoplasma infections appears to be related to the ability of the organisms to evade these 
nonspecific defense mechanisms (50, 73). In general the innate responses that occur with 
mycoplasmal respiratory diseases are the mass infiltration of alveolar macrophages (the 
predominant phagocyte in the normal, noninflamed respiratory tract) and polymorphonuclear 
leukocytes (neutrophils), and the persistence of mycoplasma antigen in the lung before the 
onset of antibody production (119). In vivo studies have shown that several factors affect the 
innate responses: 1) The strain of mycoplasma (50, 73), mouse (56), or rat (177) used is 
critical. 2) Different types of phagocytic cells have varying degrees of mycoplasmacidal activity 
(74). Alveolar and peritoneal macrophages differ in their metabolism, enzyme content, and 
bactericidal activity. Alveolar macrophages from rats exert their anti-mycoplasma effect 
regardless of the presence or absence of specific antibody. 3). The presence of NK cells in the 
lungs is also critical. It has been shown that NK cells are the principal cells responsible for 
mycoplasmacidal activity in the respiratory tract of mice (50, 95-97, 99). 4) Environmental 
factors like NO? (53, 142) may also play a role. 
Complement 
Complement has a confirmed role as a noncellular immune defense factor. Complement 
aids in antibody- and macrophage-mediated killing of mycoplasmas (199, 203). Several 
mycoplasma species both bind antibody rapidly and directly activate complement through either 
the classical or alternative pathway as well as interacting with Cl component directly (211) . 
Mycoplasmas are also susceptible to lysis by activated complement (22). 
Phagocytes (macrophages and neutrophils) 
Neutrophils and macrophages are the main mediators of immunity to mycoplasmas at the 
onset of infection ( 119). Some comprehensive reviews detailing the earlier studies on 
mycoplasma macrophage reaction are (31, 47, 74, 75). Neutrophil-rich exudates are incapable 
of clearing M. pulmonis from the peritoneal cavity of mice whereas macrophage exudates can 
do so (74). Overall, the fact that mycoplasmas are phagocytosed but still cause disease in 
antibody deficient subjects suggests that phagocytosis is not an adequate defense mechanism 
(211 ). 
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M ycoplasmas persist in the lung parenchyma despite the presence of phagocytes (73, 201) 
which has caused an interest in studying the interaction of mycoplasmas with macrophages. 
Most of the in vitro studies showed that mycoplasmas attach and multiply on the surface of 
macrophages, and without the addition of specific antibody (67, 201), the macrophages were 
incapable of ingesting mycoplasmas (199). M. pulmonis can also induce the release of 
hydrolytic enzymes from macrophages (203). Several experimental techniques like 
immunoflourescence (109), and recently colloidal carbon clearance from the lungs (87), have 
been developed to observe the in vivo effects of mycoplasmas on the phagocytic activity of 
macrophages in rats and mice. Recent in vivo studies contradict these in vitro studies, and 
suggest that specific antibody is not necessary for killing of mycoplasmas in the lung (142). 
A recent review discusses the stages of phagocytosis that could potentially be avoided by 
mycoplasmas and thus explain why phagocytosis is not a protective defense mechanism in 
mycoplasmal infections (119). In vitro experiments have shown that in the absence of 
opsonins, M. pulmonis attaches to the surf ace of macrophages but is not ingested. During this 
first stage of attachment and engulfment, specific attributes of mycoplasmas offer multiple 
explanations for escape. Mycoplasmas can avoid this first stage by their filamentous 
morphology ( 118) or by their possession of antiphagocytic proteins on their membrane. For 
M. pulmonis this resistance to ingestion is trypsin-sensitive suggesting the presence of such a 
surface protein. Also, their capsular material could mask their high hydrophobicity and thus 
decrease phagocytosis. Additionally, several mycoplasmas have the ability of binding the Fe 
portion of immunoglobulins (3, 182). The most obvious reason for inefficient phagocytosis is 
localization of mycoplasma between cilia and cytoplasmic processes. This makes them 
inaccessible to most phagocytes. The second stage that mycoplasma can affect phagocytes is in 
the phagosome. They can affect the integrity of the phagosome membrane by causing 
phagocyte metabolism and activation or respiratory burst (119). Mycoplasmas do this by 
producing proteases, lipases and phospholipases (13), and oxygen radicals (7). The third stage 
at which mycoplasmas can have an effect is the phagosome-lysosome fusion. This process 
could be impaired by the production of ammonia by mycoplasmas. The last, most unlikely 
scenario is that mycoplasmas may just survive phagocytosis (211) and escape into the 
cytoplasm through an unknown mechanism. Evidence so far does not prove whether 
phagocyte activation is induced by mycoplasmas directly or indirectly via cytokine production. 
Alveolar infiltration of macrophages and polymorphonuclear lymphocytes have been observed 
in mice injected with live, killed, or membrane preparations of MP suggesting that mycoplasma 
antigen alone may be sufficient to attract phagocytes to foci of infection thereby stimulating 
inflammatory responses (35, 176). Stuart et al. showed that M. arginini and M. arthritidis act 
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on bone-marrow derived (BMM) macrophages by indirectly stimulating the production of 
soluble factors (194). 
In addition to all of these direct effects of mycoplasmas have on macrophages, there are 
several nonspecific effects mycoplasma exert. Interestingly, all of these mycoplasmal 
nonspecific effects can be seen also on B cells. These include rnitogenic and chemotactic 
effects, and induction of class II MHC. Although most mycoplasmas stimulate primarily B 
cells, mycoplasma species differ in their ability to induce proliferation of BMM macrophages 
(194). M. pulmonis did not induce proliferation of BMM macrophages. Ross et al (165) 
demonstrated that M. pulmonis membrane preparations possess a potent chemoattractant 
activity for peritoneal and alveolar macrophages from fresh rat serum. These studies have been 
corroborated by Meier et al. (122) and Komatsu (91). Some species, including M. pulmonis, 
have been shown to induce Class I and II MHC surface expression on a variety of cell types 
including primary bone marrow macrophage cultures (193), and cultures from several different 
murine and human macrophage cell lines (193). This factor has been designated MlaF 
(mycoplasma-Ia induction factor) (193). Mlaf could be a membrane component or a secreted 
factor consisting of a protein, glycoprotein, lipoglycan, or Ii po protein. It is resistant to heat 
treatment like some rnitogens of mycoplasma species (47). The mechanism(s) responsible for 
the increase in MHC expression is not known. Evidence shows that it probably does not 
involve either the production cytokines IFN-y, IL-4 or GM-CSF ( 192). The induction of MHC 
expression in macrophage cell lines and cultures is due directly to an increase in the 
transcriptional activity of MHC genes (164, 193, 195). The significance of this event is that it 
enhances the antigen presenting ability of the cells involved. This could cause Ia expressing 
cells to be capable of presenting a variety of antigens to host T cells which is not necessarily 
beneficial because it enhances not only a specific immune response to mycoplasmal antigens 
but also to host cells expressing elevated levels of Ia. This might result in the inappropriate 
presentation of self-antigen to T cells and the development of autoimmune disease. 
One beneficial consequence of this mycoplasma-macrophage interaction in the host is that 
certain mycoplasma species can cause macrophages to be tumoricidal (28, 114, 197). It has 
been shown that activated macrophages maintain the ability to specifically recognize and lyse 
tumor cells in vivo. M. gallisepticum in concert with IFN-y causes macrophages to be 
tumoricidal (197). The macrophage activating factor, Mf-B, is stable biochemically and has 
been shown not to be a protein (197). A purified highly hydrophobic active component from 
M. capricolum's membrane also activates macrophages to tumor cytotoxicity (28). It has also 
been shown that M. orale and Spiroplasma activate the tumor killing activity of macrophages. 
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The mechanism by which mycoplasmas activate macrophages has been shown to be different 
from that of LPS (174, 196), but little else is known. 
Natural Killer CNK) cells 
One of the less well-documented, but recent findings on mycoplasmal immunomodulatory 
effects, is that IFN-y and natural killer (NK) cells are involved in resistance to M. pulmonis 
infection (95, 99). NK cells are a subpopulation of lymphoid cells which spontaneously lyse a 
limited number of tumor cells and virus-infected cells in vitro without prior sensitization of the 
host. Humoral and cellular immunity are inhibited by M. pulmonis, but NK function is 
enhanced within 24-hours after infection (95, 101). Activated NK cells function in resistance to 
early stages of infection with M. pulmonis (95). NK cells of infected mice can directly inhibit 
colony formation by M. pulmonis in vitro and can eliminate viable M. pulmonis from the lungs 
in vivo (99). The most convincing evidence that stimulated NK cells can indeed have anti-M. 
pulmonis activity is the reduced resistance to infection of C.B-17 SCID mice when NK cells 
and their products were depleted (99). 
The mechanism by which NK cells lyse M. pulmonis lysis is unknown (99). M. pulmonis 
may augment NK cells in mice by inducing the secretion of interferons and/or interleuk.in-2 
(27, 106, 160). One possible mechanism is that the NK cells secrete IFN-y on exposure to M. 
pulmonis. IFN-y secreted from NK cells has the ability to activate mouse macrophages in vitro 
and in vivo which would lead to macrophage activation and mycoplasmal killing. Another 
possible mechanism is the association of a protease or lysolecithin, or both, with lower NK 
activity are directly responsible for the killing of M. pulmonis. 
Adaptive immunity 
Adaptive immune mechanisms are better understood than the innate immune mechanisms, 
yet the interaction of circulating antibodies, local secretory antibodies, NK cells, and cell 
mediated immunity (CMI) during mycoplasmal disease is not known. Even the type of immune 
response, humoral or cellular, that is most effective in the protection against or resolution of the 
infection is not known (176). Mice and rats resolve the disease process differently (37, 108, 
109), and in mice, a humoral response appears to be necessary for the alleviation of the disease 
process and prevention of future infection. This is supported by the fact that the passive 
transfer of serum antibodies to mice intranasally or intravenously protected these mice against 
intranasal challenge with M. pulmonis (75, 199, 202). This passive transfer of serum 
antibodies did not affect rats. Instead, cellular immunity in rats appears to play the major role in 
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the prevention of disease and the resultant of lesions. Adoptive transfer of immunity by spleen 
cells, not sera, was protective in rats (34, 75, 98). Although a humeral response can be 
detected in rats during infection, it appears to have no effect in the progression of disease (58). 
Humeral immunity 
Antibody could protect against mycoplasma infection by several mechanisms: inhibition of 
attachment, inhibition of growth or metabolism, opsonization, or promotion of complement 
killing. One of the major functions of antibody is the conferral of resistance against infectious 
agents. Recovery from naturally occurring or experimentally-induced MRM results in 
immunity; reinfection can occur but there is protection against development of subsequent 
MRM. Also, specific antibody of any immunoglobulin class present in the respiratory tract 
seems to be capable of conferring resistance to mycoplasma respiratory infections ( 199). 
Humeral antibody also serves as another advantage in both humans and animals by preventing 
dissemination of mycoplasma infections to systemic tissues (177). In the absence of antibody 
but the presence of complement, it has been reported that neutrophils or PMNL's phagocytose 
mycoplasmas and disseminate them to joints where the mycoplasma survives in the absence of 
antibody. The presence of antibody seems to be prevent this systemic spread of the infection 
(211). 
Systemic antibody responses to mycoplasma have been studied extensively. Serum IgM 
responses appear first and remain throughoutinfection (35, 177, 182). Serum IgG responses 
are usually detected next, but this varies with the mycoplasma, the host, _and the route of 
infection. There is a preference in some animals for the production of a particular 
immunoglobulin subclass. F344 rats preferentially produce serum IgG2b, but LEW rats do not 
show a similar preference (175). This preference for a particular IgG subclass has been 
described for M. bovis infections in cattle as well. Regulation and development of IgG 
subclass responses are probably important in defense mechanisms against many mycoplasma 
diseases ( 117), but the development of serum antibody does not result in recovery from 
chronic lung disease in mice or rats (29). 
Since serum antibody is ineffective in clearing mycoplasma infections, the local immune 
mechanisms may play a greater role in the resistance to mycoplasma infections of the 
respiratory tract. Secretory immunity serves to protect the mucosal surfaces from disease by 
inhibiting adherence of bacteria to epithelial surfaces and by neutralizing bacterial products such 
as toxins and enzymes (190). Antibody-producing (plasma) cells are present in the lungs of 
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animals infected with M. pulmonis (35). In rats, the upper respiratory nodes (URN) are the 
initial and major sites of antibody production throughout the course of disease (1 80, 181). 
Many studies have included experimental designs to examine both systemic and secretory 
responses. These studies showed that IgG antibody is frequently the predominant class in lung 
washings, particularly following systemic and combined systemic and local routes of antigen 
presentation. Even following local infection only, IgG is a major component of the local 
response (35, 200). Rose and Cebra (162) showed that B cells display an isotype commitment 
of IgG 1 after different modes of mucosal stimulation with M. pulmonis. This is an isotype that 
is not ordinarily predominant after mucosal stimulation. Chronic stimulation with M. pulmonis 
lead to an increase of antigen-specific B cells in all lymphoid tissues (163 ). The majority of T-
dependent clones generated in vitro by primed B cells in vivo secrete exclusively IgG 1 (163). 
Thus, it appears that IgG 1 is the predominant isotype expressed by antigen-specific B cells 
after chronic mucosal stimulation or stimulation via other routes in normal and athymic mice. 
This predominance of IgG 1 secretion by clones from M. pulmonis primed B cells must be due, 
at least in part, to the peculiar stimulatory effect of the M. pulmonis antigens on specific B 
cells. The majority of M. pulmonis specific B cells are slgG 1 +and slgD- (163). To complicate 
the situation, recent articles have showed that some mycoplasmas have Fe receptors (3) and 
contain IgA proteases. In summary, antibody responses play a limited role in the host's 
recovery from infection (182) since even in mice the production of local and systemic 
antibodies does not prevent the chronic nature of MRM. 
Cell-mediated immunity CCMD 
Since humoral immunity cannot prevent the chronic nature of MRM, studies on cell-
mediated immunity (CMI) have been performed to determine what effects it has on MRM 
pathogenesis. It has been shown that M. pulmonis functions as both a T-dependent and T-
independent antigen (162). CMI has three main functions: 1) T cell proliferation and 
elaboration of mediators in response to specific antigens. Both IL-2 (106) and IFN (192) 
production are induced by M. pulmonis - demonstrating that T cells are involved; T cells 
proliferation and differentiation into specific cytotoxic killer cells; and 3) T cells serve as helper 
or suppressor cells regulating both T-cell functions and B-cell antibody production (75). The 
role of T-cell subsets in pathogenesis needs to be explored, particularly in relationship to 
resistance to mycoplasmal disease. A predominant feature of the histopathology in many 
mycoplasma infections is an accumulation of lymphoid cells, the majority of which contain 
immunoglobulin (35). In F344 rats infected with M. pulmonis, the proliferating lymphocytes 
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appear to be mainly T cells and null cells (55, 58). Differences in the proportion of TH cells in 
rats appears to be related to the severity of M. pulmonis lung disease (57); there is a greater 
proportion of TH cells found in susceptible strains of rats. To further determine the effects of T 
lymphocytes during M. pulmonis infection, athymic nude mice were used to assess the 
chronicity of induced arthritis (89). It was concluded that the T-cell element of the immune 
response to M. pulmonis was important in both the prevention of and recovery from disease 
since impaired T-cell function predisposed the mice to a severe degree of chronic arthritis as a 
result of their failure to eliminate the causative organisms (89). Rats and mice that are deficient 
in T cells also develop less severe respiratory disease than do immunocompetent animals after 
infection with M. pulmonis (59). To develop a full-fledged interstitial pneumonia, one requires 
the participation of T cells and their products (106, 131 ). 
Although numerous investigations have addressed the question of host defense in 
mycoplasmal infections of the respiratory tract (131, 177), none as yet has defined the essential 
mechanisms involved in protective immunity against these organisms. Ongoing studies are 
evaluating whether lymphocyte responses play a protective role in preventing dissemination of 
M. pulmonis to extrapulmonary tissues and death, or whether lymphocyte responses contribute 
to disease severity and clinical symptoms. The humeral response could contribute to disease 
pathogenesis through the development of hypersensitivity responses or the deposition of 
immune complexes (182). The high serum IgG responses within C3H/HeN mice and LEW 
rats correlated with more severe lung disease. This specific immune response contributed to 
disease by an unknown mechanism (29). Cartner et. al. (29) suggested that effective innate 
host defenses are more important than the adaptive immune responses. 
Nonspecific interactions with host defenses 
Nonspecific effects of mycoplasmas on B and T cells 
Mycoplasmas are able to modulate immune responses nonspecifically. One of the ways 
they accomplish this is through polyclonal activation of lymphocytes. Lymphocytes react with 
mycoplasmas in a variety of ways. Both stimulation and suppression can occur as a result of 
antigenic-specific or mitogenic (nonspecific) responses by the immune cells involved (1 , 2, 67, 
101, 170). It is well-documented that mycoplasmas and or substances isolated from 
mycoplasmas have the potential to activate lymphocytes from their original host as well as 
lymphocytes not from their original host (14, 16, 17, 40, 132). A wide variety of pathogenic 
and nonpathogenic mycoplasmas have these mitogenic properties (137). The subpopulations of 
lymphocytes (B cells, T cells, or both) that are polyclonally activated also vary with species 
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(14-16, 127, 129, 133-135, 213). In addition, different mitogenic capacities are exhibited by 
various strains of the same mycoplasma species tested in parallel (137). These mycoplasmal 
mitogens not only differ in the lymphocyte subpopulation(s) they activate, but also in the 
resistance of their mitogenic activity to heat treatment (16, 40, 69, 135, 137). The majority of 
these mitogens identified cause polyclonal activation of B cells (132, 137). The B cell blasts 
generated mature into terminally differentiated plasma cells secreting immunoglobulins of 
specificities not related to the stimulating agent. Nonspecific T cell activation by mycoplasma is 
less common (67). M. arthritidis mitogen (MAM) is the most well-characterized mycoplasma 
T-cell mitogen ( 42). Even though mitogenesis is nonspecific, the regulation of these organism-
host interactions is not random (42, 67). The control mechanisms for lymphocyte activation by 
MAM are well described (41, 44-46) and those for the M. pulmonis mitogen(s) are beginning 
to be understood. 
The original report by Ginsburg and Nicolet (69) proved that in vitro-cultured rat 
lymphocytes were stimulated by M. pulmonis. Later it was shown that M. pulmonis has 
mitogenic activity towards both rat B- and T-lymphocytes. M. pulmonis also induces the 
development of antibody producing cells (APC) (133) . M. pulmonis has a stronger effect upon 
B cells and less so on T cells (133). Only a portion of the lymph node T-cell population 
responding to either ConA or PWM is activated by M. pulmonis. The biochemical 
characterization of M. pulmonis showed its mitogenic activity was abolished upon heating 
( 135). Whereas the mitogens of M. arthritidis, A. laidlawii, and M. pneumoniae were heat 
stable (127). Outer surface proteins appear to be major constituents of the M. pulmonis 
mitogenic factor(s) (127). Membrane carbohydrates, but not lipids, may also be involved in the 
mitogenicity of M. pulmonis (127, 135). It is still not certain whether the same membrane 
mitogenic factor(s) are responsible for the activation of both Band T cells. Different mitogens 
within the membrane may stimulate different subpopulations of lymphocytes (127). 
Mitogenicity (as defined by in vitro assays) (181, 213) of M. pulmonis resides within its 
membranes, but in vivo tests of mitogenicity (57, 129, 131) are the ones that will indicate a 
correlation of mitogenicity and pathogenicity. Naot et al. used nonviable M. pulmonis cells to . 
show that nonspecific activation of T cells was a major cause of the pneumonia seen in MRM, 
but they failed to show a clear role of B cell activation in M. pulmonis pathogenesis ( 129). 
Nonspecific activation and recruitment of B cells occur during the development of MRM ( 181). 
Its possible that the mitogenic and differentiative activities of M. pulmonis surface proteins may 
promote nonspecific proliferation and differentiation to antibody-producing plasma cells in vivo 
(165). 
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Mitogenic stimulation of host lymphocytes by M. pulmonis membrane mitogens is believed 
to be a major factor in the development and severity of lung diseases produced by this 
organism in rats (129). The crucial question is whether or not nonspecific, polyclonal 
lymphocyte activation plays any role in mycoplasma disease (131, 178). Evidence supporting 
the role of mitogenesis in M. pulmonis pathogenesis is the following: 1) Rat strains which give 
the strongest mitogenic response to M pulmonis develop the most severe respiratory lesions. 
LEW rats (the more susceptible rat strain) develop greater in vitro lymphocytes responses to M. 
pulmonis mitogens than do F344 rats (57, 176). 2) Administration of mitogenic M. pulmonis 
membranes induces pulmonary lesions characterized by lymphoid infiltrates predominantly in 
the alveolar region rather than in the bronchial regions, as occurs with natural disease (129) . 
There is also evidence that it is unlikely that all of the phenomena seen in mycoplasma 
infections are directly related to this nonspecific lymphocyte activation (214). The role of 
nonspecific activation by M. arthritidis in disease pathogenesis remains unclear. The ability of 
M. pulmonis to directly activate polyclonally and cause proliferation and differentiation of B 
lymphocytes may play a role in the large number of B cells and plasma cells seen in lung 
lesions of MRM. There are· alternative hypotheses, however, describing the purpose or 
consequences of this mitogenic effect of mycoplasmas. For instance, polyclonal activation 
could stimulate the development of autoimmune disease. Another potential consequence of 
polyclonal activation is altered immune responses to non-cross reacting antigens resulting in the 
generation of antibody responses to unrelated antigens (181, 213). Both enhancement and 
suppression have been documented following infection with M. pulmonis and M. arthritidis. 
Suppression of responses to unrelated antigens may be related to disruption of 
immunoregulation (31). The mechanisms and consequences of this polyclonal activation have 
yet to be defined. It is still controversial whether this activation of host immune cells leads to 
the development of specific autoimmunity or whether it represents simply an aggravated 
inflammatory response (193). 
In addition to activating lymphocytes, M. pulmonis is capable of producing chemotactic 
factor(s) for B cells and macrophages (165). This is the first description of a bacteria-derived 
chemoattractant for B lymphocytes. The chemotactic activity of M. pulmonis may explain one 
of the most prominent pathological signs seen in a the majority of chronic mycoplasma 
infections, the infiltration of large numbers of mononuclear cells. This chemotactic ability could 
provide an explanation as to why B cells form an early persistent component of the lesions of 
MRM (165). The chemotactic factor is sensitive to trypsin and protease treatment (165). 
Currently it is thought that this activity is mediated by surface membrane proteins of M. 
pulmonis because the major variable surface antigen of M pulmonis, V-1 (210), possesses this 
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in vitro B lymphocyte recruitment activity to a marked degree. This chemotactic factor -is 
resistant to heat treatment and solubilization, unlike the M. pulmonis rnitogen. Thus, 
chemotaxis and rnitogenesis are not necessarily linked to the same mycoplasmal component. 
One model would specify that the role of the chemotactic factor is to promote the initial 
recruitment of B lymphocytes to the lung during the early stages of MRM where the rnitogen 
would then promote lymphocyte blastogenesis perpetuating chronic pulmonary inflammation 
(182) . 
M. pulmonis has been shown to up-regulate MHC class II expression on resting murine B 
lymphocytes by an as yet undetermined mechanism (164). This investigators suggest that the 
induction of Ia hyper expression may be a necessary event for B-cell proliferation. Hyper 
expression of Ia on macrophages and B cells may prepare them for interaction with TH cells 
(178). The Ia induction by mycoplasma is polyclonal and non-antigen specific, and thus, may 
lead to an increased potential for response to self-antigens and autoimmunity (178). 
Alternatively, this increase in MHC class II expression might promote a more efficient immune 
response to the organism by increasing macrophage and B cell cooperation with TH 
lymphocytes ( 178). 
The cumulative effects of all of these nonspecific interactions may be substantial (182) . All 
of the above interactions of M. pulmonis with the host defense system may be involved in 
lesion development and the survival of the organism since most mycoplasma infections are 
chronic (182). The mechanisms and consequences of the polyclonal activation, chemotaxis, 
and induction of MHC class II expression on lymphocytes have yet to be defined. The 
rnitogenic activity for B cells, ability to enhance Ia expression, and modulation of other host 
responses may promote in situ proliferation of lymphocytes and macrophages to perpetuate 
chronic pulmonary inflammation ( 165). The potential consequence of this level of nonspecific 
polyclonal activation of lymphocytes may determine the severity of lesions through either the 
release of chemotactic factors and lymphokines thus leading to increased infiltration and 
activation of lymphoid cells or the activation of autoimmune clones. However, polyclonal 
activation of lymphocytes need not actually play a direct role in disease pathogenesis since the 
immunoregulatory mechanisms which affect polyclonal activation may also function to control 
the development of other immune responses such as hypersensitivity reactions (176). 
Additional work in this area is needed to demonstrate the significance of these phenomena in 
VlVO. 
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Cytokines 
Cytokines are soluble molecules produced by immune cells that function as transmitters for 
intercellular communication (192) and thereby modulate the host immune response. They have 
both stimulatory and inhibitory effects on cells involved in the immune response (192). The 
purpose of studying mycoplasma effects on cytokine production is to determine whether a 
specific effect is due directly to the action of a mycoplasmal product on the cell or indirectly 
through the stimulation of cytokine production ( 170, 192). The ability of mycoplasmas to 
induce cytokine production in immunocompetent cells has been known for some time, but little 
information has been reported about the production of cytokines or their involvement in the 
pathogenesis of respiratory mycoplasmal infection (65). It has been shown that cytokines are 
important mediators in both lung defense and inflammation (88). Cytokine production is also 
involved in the pathogenesis of lung inflammatory disease (65). The capacity of mycoplasmas 
to induce proinflammatory cytokines seems to be a general phenomenon shared by very distant 
species (147). 
Various mycoplasma species have various effects on the induction of cytokines: IL-1, IL-2 
(11, 115), IL-4 and IL-6, TNF-a, IFN-a, -~,and -y (7, 10, 18), GM-CSF (68, 194). Several 
mycoplasma species or mycoplasmal components have been found to induce proinflammatory 
cytokines like TNF-a (4, 107, 174, 196), IFN-y (90, 99), IL-1 (4, 90), and IL-6 in vitro by 
monocytes and resident macrophages (25, 92, 174). 
Recent studies have demonstrated that the genes of several cytokines are expressed in mice 
following experimental infection with either M. pulmonis (139) or M. pneumoniae (143). 
Faulkner, et. al. (65) showed the sequential appearance of cytokines in the lungs of infected 
mice; TNF-a was first followed by IL-1, IL-6, and finally IFN-y. Since different mouse 
strains (C3H/HeN & C57BL/6N) display different susceptibilities to M. pulmonis, it was of 
interest to determine if this could be related to cytokine production. C3H/HeN mice had higher 
and more persistent concentrations of TNF-a and IL-6 in bronchial alveolar lavage fluid than 
did C57BL/6N mice. This suggests that TNF-a and IL-6 may be important factors in 
pathogenesis of acute M. pulmonis disease in mice. Pathologic findings may in part be 
attributed to TNF-a released from macrophages (6, 174, 196). M. pulmonis was also found to 
trigger rat lymphocytes to secrete IL-2 (106). The significance of IL-2 production after 
exposure of cells to M. pulmonis mitogens is not the production of cytotoxic lymphocytes to 
mycoplasma-infected cells, but as an amplifier of the inflammatory response through the 
augmentation of B cells and the TH response. 
The mechanism by which mycoplasmas induce the production of cytokines has yet to be 
determined. It has been reported that protein-kinase C (PKC) and intracellular Ca2+-related 
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biochemical events play key roles in the activation of cytokine production by immune cells (76, 
93). Yet, no one has addressed the specific mechanisms by which mycoplasmas induce the 
production of proinflammatory cytokines. Previous studies have shown that the cytokine 
induction by M. fermentans, M pneumoniae, M penetrans, and M. arginini was restricted to the 
lipid membrane constituents or lipoprotein fractions (147). Researchers have also compared the 
activities of different mycoplasma preparations with that of LPS (147, 196). The signal 
transduction pathways involved in cytokine induction by mycoplasmas has been studied and 
showed that mycoplasma activates a biochemical pathway different from that triggered by LPS 
(196). LPS uses a PKC pathway to stimulate TNF production in mouse peritoneal 
macrophages (185). Mycoplasma-induced TNF production involves a Ca2+-dependent, but not 
a PKC dependent, biochemical pathway. This induction of TNF production by mycoplasmas is 
not mediated by prostaglandin E2 (PGE2) secretion from cells nor by a cyclic nucleotide acting 
as an intracellular second messenger (196). It was also shown that mycoplasma induces TNF 
production at the level of transcription of the gene. Further studies showed that tyrosine 
phosphorylation is a key event in the mycoplasma-mediated induction of proinflammatory 
cytokines IL-1~, TNF-a, IL-6, like LPS (147). Unlike LPS, however, mycoplasmas were 
unable to induce the phosphorylation of some high molecular weight proteins. Thus, 
mycoplasmas can induce cytokine production by specific pathways which may overlap with, 
yet remain distinct from, those triggered by LPS (147). 
This research proves that many of the activities associated with the modulation of 
immunocompetent cell activity and function by mycoplasmas have been shown to be due, at 
least in part, to the induction of immune reactive cytokines (192). Most likely an interplay 
between multiple immunologic processes, and not a single immunologic response, ultimately 
determines the severity and progression of MRM (176). Further studies are required to fully 
characterize the types of immune responses involved, and to determine how they interact. 
Bacterial protein hemolysins ( cytolysins) 
Extracellular proteins with hemolytic or cytolytic activities are produced by a large variety 
of gram-positive and gram-negative bacteria (5, 80, 191). Much work has been done on red 
blood cells even though hemolysis is rarely ever a feature of the diseases caused by the 
pathogens which elaborate these toxins. Red blood cells are convenient to obtain and handle in 
large quantities, and they possess a simple and sensitive indicator system to demonstrate 
membrane damage when it occurs. Since many bacterial hemolysins act on cells other than red 
blood cells, the term cytolysin describes more accurately the range of their biological activities. 
The principal sources of cytolytic peptides are bacteria, higher fungi, cnidarians (coelenterates) 
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and the venoms of snakes, insects, and arthropods. The mechanism of action and the toxin's 
relation to pathogenesis is an active area ofresearch today (39, 161). One of the larger, well-
characterized group of hemolysins are the pore-formers (21). This review will focus on the 
predominant Gram positive hemolysins (cytolysins) known. 
Pore-forming hemolysins 
Gram positive pore-forming toxins are generally produced as soluble proteins that 
aggregate into supramolecular complexes of various sizes on the membrane and ultimately end 
up as membrane-associated complexes forming pores of a defined size (209). As more of these 
toxins are discovered and studied, classes based on similarities in mechanism and/or primary 
sequence are becoming evident. Some cytolytic proteins have clearly evolved from a single 
progenitor gene (convergent evolution) and others may share mechanistic features, but lack 
sequence similarities (divergent evolution). The staphylococcal 8 and a toxins are both pore-
formers with quite different physical characteristics that seem to be derived by the divergent 
evolution. Clostridium perfringens, Staphylococcal aureus, and Streptococcal pyogenes 
produce several different cytolysins. 
Thiol-activated cytolysins 
This group of cytolysins make up the largest group of related cytolytic proteins produced 
by the Gram positive bacteria. These cytolytic proteins are found in four genera of Grarn-
positive bacteria - Clostridium, Streptococcus, Listeria, and Bacillus. This group of pore-
formers share many characteristics: they are inactivated by mild oxidation and reactivated by 
reduction with thiol reagents or sulfhydryl compounds; they are irreversibly inactivated by 
small amounts of cholesterol and stereo-specifically related sterols (suggesting they use 
cholesterol as their receptor); they are lethal and cardiotoxic; apart from their much studied 
hemolytic property, thiol-activated cytolysins are known to interact with a variety of 
leukocytes, in particular those involved in defense mechanisms (191); and they display 
immunological cross-reactivity. The proposed mechanism of action of these pore-formers is 
that they initially bind to cholesterol, a temperature independent step, and then upon warming 
to 37°C, they oligomerize and form supramolecular complexes varying in structure from arcs 
and C-shapes to closed rings composed of a variable number of toxin monomers. A complete 
listing of the sequenced thiol-activated hemolysins has been compiled (209). The most studied 
of these are LLO (listeriolysin O; from Listeria monocytogenes), PLY (pneumolysin; 
Streptococcus pneumoniae), SLO (streptolysin O; Streptococcus pyogenes), and PFO 
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(perfringolysin O; Clostridium perfringens) (21). In contrast to the other thiol-activated 
cytolysins, PLY is not secreted (209). Sequence analysis of many of the genes for these toxins 
have shown that all but IVO (ivanolysin; Listeria monocytogenes) have a single cysteine in the 
mature protein. This cysteine is invariably present in a conserved 11-residue peptide with the 
sequence ECTGLA WEWWR. Multiple studies have been performed mutagenizing this 11-
residue peptide to find the purpose of the conserved cysteine (209). These studies clearly 
showed that the sulfhydryl of the single cysteine was not required for activity, but it contributes 
to the overall structure of this domain. Cysteine substitution mutants were no longer subject to 
oxidative inactivation and thiol-activation, suggesting that the cysteine residue is responsible 
for these properties (21). Although the sulfhydryl function of the essential cysteine is not 
necessary for the activity of these toxins, the cysteine is clearly in a sensitive site that cannot 
withstand chemical modification. There is no obvious role for the highly conserved 11-residue 
region. This region may interact with the sterol after membrane binding or may trigger a post-
binding conformational change that readies the protein for oligomerization (209). Thus, the 
term "thiol-activated" is no longer a true description of these toxins (209). 
Lytic peptides which alter permeability to allow passage of ions (colloid osmotic lysis) _ 
Hemolysis reactions by thiol-activated cytolysins, unlike several other cytolysins, do not 
involve a colloid osmotic mechanism. Both S. aureus a toxin and the Gram-negative toxin 
aerolysin form pores and cause lysis of the colloid-osmotic type. Being the first cytolytic 
protein to be identified as a pore-forming toxin, S. aureus a toxin is the best cha,racterized 
toxin in this group. This toxin forms a hexameric oligomer on the membranes (209). Like the 
thiol-activated cytolysins, a toxin binds to the membrane, diffuses laterally, and oligomerizes 
with other toxin monomers to form a pore in the membrane. Unlike the thiol-activated toxins 
using cholesterol as their receptor, no specific receptor is required for a toxin. Band 3 protein 
of erythrocytes may be the a toxin receptor (209). Aerolysin has been found to use a specific 
glycoprotein receptor (12). 
Channel-forming agents 
This group of toxins are small, secreted peptides which display a detergent-like action. 
Most toxins in this group are found in arthropods (bees, wasps, hornets, bumblebees, and 
ants), fungi, and sea anemones (12). Theo toxin from Staphylococcal aureus belongs to this 
group. This toxin is a 26 residue secreted peptide, contains no cysteine in its sequence, and is 
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composed of a high proportion of hydrophobic amino acids unlike most pore-formers which 
are mainly hydrophilic in nature. Other unique characteristics are its thermostability, inhibition 
by serum lipoprotein and phospholipids, and low specificity for red blood cells of different 
species. The 8 toxin is a relatively weak toxin that forms a pore of monomers into a barrel-
stave structure (209) thus forming channels in lipid bilayers. 
Phospholipases 
Phospholipases are classified according to their site of action on the phospholipid molecule. 
They are a group of bacterial membrane-active toxins with enzymatic activities. They also 
disrupt membranes and lead to lysis of cells by enzymatic degradation of membrane bilayer 
phospholipids. Hydrolysis of the phospholipids in a cell does not necessarily lead to cell 
disintegration, however. Phospholipase A is membrane-associated and is present in the 
venoms of most snakes and in the venoms of a considerable number of arthropods (12). It 
produces limited hydrolysis of erythrocyte phospholipids but is not hemolytic itself. Some 
Mycoplasmas have been found to contain phospholipase A1. Phospholipase D is also not 
cytolytic. It is produced by Corynebacterium pseudotuberculosis and Corynebacterium 
ulcerans and is a constituent of the venom of the brown recluse spider ( 12). Phospholipase D is 
specific for sphingomyelin and lysophosphatidylcholine. Cytolytic as well as non-cytolytic 
Phospholipases C have been described for many other bacterial species (12). One of the most 
studied, that of the gas gangrene causing Clostridium peifringens is one of the most thoroughly 
studied of the Phospholipase Cs. 
Cytopathic effects caused by mycoplasmal toxins 
In contrast to the gram-positive and gram-negative bacteria, most species of mycoplasmas 
do not produce toxins (154, 179). M. neurolyticum, M. gallisepticum, M. arthritidis, M. 
pulmonis , M. hyopneumoniae, M. bovis, and M. mycoides are the most familiar species of 
mycoplasmas that are known to be toxic for the animals in which they are pathogens. The toxin 
that M. neurolyticum makes produces the well-researched "rolling-disease" in mice. Both the 
toxins of M. neurolyticum and a variant of M. gallisepticum have been identified as 
neurotoxins. The neurotoxin of both of these mycoplasma strains appear to have similar in vivo 
biological effects, except that the M. gallisepticum neurotoxin has not been shown to be an 
exotoxin like the neurotoxin of M. neurolyticum. M. arthritidis and M. pulmonis both have 
been found to be toxic for mice and rats. Their toxins share similar attributes to M. 
gallisepticum except that there are no specific neurological manifestations. 
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A membrane-associated hemolysin (mHL) in M. pulmonis has been studied as a possible 
toxin or virulence factor. Initial studies showed that the mHL required a serum cofactor such as 
BSA for activity, was trypsin-sensitive and was only active at temperatures above 22°C (125). 
This mHL activity is a common activity in the Mollicutes (126). Further biochemical analyses 
showed that this mHL was inhibited by a sulfhydryl inhibitor (NEM) and oxidizing agents 
(iodoacetate, and hydrogen peroxide); it was activated by sulfhydryl activating compounds 
(cysteine, dithiothrietol, ~-mercaptoethanol, sodium thiosulfate); and cholesterol as well as 
other sterols inhibited mHL activity (79). These characteristics share strong similarities to the 
gram-positive thiol-activated cytolysins. The only difference is they both display different 
stereo-specificity requirements for cholesterol inhibition (79). 
Four hypotheses have been proposed as a mechanism of action of this activity (123). 
Soluble metabolic products such as H202 that can damage RBC membranes in relatively high 
concentrations, but mHL activity was not diffusible and could not be inhibited by catalase or 
pyruvic acid (125). Alterations of RBC lipids by a mycoplasma-associated phospholipase 
could result in membrane damage, but previous studies have failed to correlate phospholipase 
C activity in mycoplasmas to hemolytic activity (126). The mHL could form a pore-like 
structure upon transfer to the RBC membrane or cause a destabilization of the RBC membrane 
through some unknown mechanism. This theory is partially supported by the similarity that 
exists between the mHL and the thiol-active cytolysins (79), but further studies are needed to 
prove or disprove this possibility. Finally, mycoplasmas could use this activity to acquire 
membrane components from their host thus causing membrane destabilization and lysis. 
Previous studies with a fluorescent cholesterol probe lend credence to this hypothesis by 
demonstrating significantly enhanced transfer of the probe under conditions conducive to lysis 
by the mHL ( 123). The research presented here focuses on further characterization of a soluble 
form of the mHL which, like the M. neurolyticum toxin, emerges as a broad, single peak in the 
void volume of a G-200 Sephadex column. 
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MATERIALS AND METHODS 
Mycoplasmas 
M. pulmonis UAB6510 was used throughout this study. Cultures were routinely grown 
from a stock culture maintained at -70°C by inoculation into a modified dialyzed medium ( 145) 
at a 1: 10 dilution and incubated statically at 37°C. These cultures were maintained by serial 
passage. Organisms were harvested by centrifugation (8000 x g, 15 minutes) at the mid to late 
log phase of growth, washed once with 0.01 M sodium phosphate - 0.14 M sodium chloride, 
pH 7.4 (PBS). Mycoplasmas were used immediately in the assays. Protein concentrations 
were determined with the Bio-Rad dye reagent (Bio-Rad Laboratories, Richmond, Calif.) 
using bovine serum albumin (BSA) as a control. 
Mice 
Pathogen-free BALB/cByJ, C3H/HeJ and C3H/He0uJ mice were obtained from 
Laboratory Animal Resources (LAR) which is a division of the College of Veterinary 
Medicine, Iowa State University, Ames, IA. These mice are monitored and tested quarterly for 
mycoplasma contamination by serological screening. These colonies are negative for all 
pathogens, and all animals were negative for IgG and IgM anti-M. pulmonis antibodies at the 
time of the experiment. 
Mycoplasma Media 
M. pulmonis was grown in a modified dialyzed medium to minimize medium 
contamination (145). The dialyzed medium base was prepared by dialyzing 220 g of brain heart 
infusion (Difeo Laboratories) and 110 g of yeast extract (Difeo) (dissolved in 1, 100 ml of 
water) against 8 L of 0.5% NaCl for 6 hat 80°C and continuing at 4°C overnight. Phenol red 
(0.001 %) was added, and the pH was adjusted to 8.0 before autoclaving. The base was then 
completed by supplementing with 10% agamma horse serum (GibcoBRL), 0.5% glucose 
(Fisher, Fairlawn, NJ), and 25 µg per ml Cefobid (Roerig-Pfizer, New York, NY). Cultures 
were harvested at mid to late-log phase as indicated by a color change in the media. For 
determining colony forming units (CFUs), mycoplasmas were grown on Broth A agar plates 
prepared as described (51). 
Radiolabeling of M. pulmonis 
Radiolabeled M. pulmonis was prepared by pelleting 100 ml of mid log-phase cultures 
grown in dialyzed media and resuspending the pellet in 25 ml of Hanks Balanced Salt Solution 
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(HESS) labeling medium (HBSS-1 % glucose-10% dialyzed horse serum-25 rnM HEPES, 
pH 8.0). Horse serum was prepared by dialysis against 40 volumes of PBS or Tris saline (TS, 
0.01 M Tris-0.14 M NaCl, pH 7.4) overnight at 4°C, followed by filter sterilization. Fifteen 
micocuries per ml of Trans[35S]label (ICN Radiochemicals, Irvine, Calif.) or 50 µCi per ml of 
[14C]amino acid mixture (ICN Radiochemicals), or 1 µCi per ml of [32P]N<tiHP04 (ICN 
Radiochemicals) was added to the labeling medium, and the cells were incubated for 4 hat 
37°C. The label was chased for 2 h with an equal volume of dialyzed media. When 
radiolabeling with [32P]N<tiHP04, extra care was taken to avoid any solutions containing 
phosphates. The culture was then pelleted, washed with PBS-1 % glucose (PBSG), and 
resuspended in 1 ml of RPMI 1640 and incubated at 37°C for 8 h. The suspension was then 
centrifuged at 15,000 x g for 20 min. The pellet was resuspended in 400 µl of water and the 
supernatant was diluted with 1 ml of RPMI 1640. Efficiency of radiolabeling was determined 
by precipitating the proteins by adding trichloroacetic acid (100 µl of a 72% solution) and 
deoxycholate (100 µl of a 0.15% solution) and counting the radioactivity of the pellet and the 
supernatant. From that information, percentage of incorporation was determined. 
Soluble Hemolysin Preparation 
The fresh mycoplasma whole cell pellet obtained from 1 liter of culture was washed with 
PBS and resuspended in RPMI 1640-25rnM HEPES-2 g Na HC03 at one fiftieth of the 
culture volume and incubated for 8 h at 37°C. This suspension will be referred to as a RPMI 
mycoplasma suspension. The supernatant was prepared by centrifuging the suspension at high 
speed (12,000 x g, 20 min) and then by ultracentrifugation (40,000 x g, 2 h). The resulting 
supernatant will be referred to as the soluble hemolysin (sHL). 
Hemolytic Assays 
Blood from mice was collected by cardiac puncture, and the mouse red blood cells were 
prepared for use in the hemolytic assay in the following way. Blood was collected in Alsever' s 
anticoagulant, and the mouse red blood cells were washed in PBS-25 rnM HEPES four times, 
treated with diphenyl carbonyl chloride-treated trypsin (T-1005, Sigma) for 1.5 h (1:1000 
dilution, 4% suspension) at 37°C with gentle agitation. The trypsin-treated mouse RBCs 
(MRBCs) were then washed in PBS-25 rnM HEPES four more times and resuspended in the 
same buffer to a final suspension of 10%. This suspension was kept at 4°C for no more than 
three days before use. 
The HL assay has been described previously (125) except that MRBCs obtained from 
BALB/cByJ, C3H/HeOuJ or C3H/HeJ mice were used. The HL assay mixture consisted of 
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MRBCs in RPMI 1640-25 rnM HEPES-1 % BSA (pH 7.4) at a concentration of 0.5% 
MRBCs (optical density at 600 nm of 0.8-0.9) and varying amounts of mycoplasma soluble 
protein in a total volume of 3 ml. The tubes were placed in a shaking water bath and incubated 
at 37°C. The optical density of the RBC suspension was measured at the beginning and end of 
the experiment, usually 90 min, and the hemolytic activity was calculated as follows: 
[(ODs - O~) I (0.5 X ODs)] I (TX mg) 
where ODs = optical density at the start of the incubation, ODE =optical density at the end of 
the incubation, T = time in hours, mg = mg of mycoplasma protein added to the reaction 
mixture. Experiments were repeated a minimum of three times. Controls consisted of MRBCs 
alone (negative control), freshly harvested mycoplasmas and MRBCs in assay medium 
(positive control). 
For blood agar plates, 2.4 g of SeaPlaque GTG low melting temperature agarose (FMC 
BioProducts, Rockland, Maine) was dissolved in 120 mls of RPMI 1640-25 rnM HEPES. 
This was allowed to cool, and then 6.06 mls of 30% BSA (Sigma), 15 mls of MRBCs (10% 
suspension), and 600 µl of 0.25% Cefobid was added. This mixture was then poured into 8 
petri-plates (Fisher) and set in the refrigerator for 1 h to allow solidification. Plates were then 
brought to room temperature and wells were punched in the agar with a pipetman. Ten to 
fifteen µl of sample were placed into the wells and the plates were placed in a 37°C incubator. 
After 4 h, the plates were examined for zones of lysis. These plates were also used to locate the 
region of hemolytic activity following native- polyacrylarnide gel electrophoresis (PAGE) by 
placing the upper half of the 3 mm gels on the blood agar and observing lysis after 4 h of 
incubation at 37°C. 
Soluble Hemolysin Release Assay 
In order to determine the relationship between viability of the mycoplasmas in RPMI 
buffer, cell lysis and the release of sHL activity, a modified assay was used. One ml aliquots 
from a 20 ml RPMI mycoplasma suspension was removed every 30 min for a total of 8 h. 
Each aliquot was then centrifuged at 15,000 x g for 15 min, and the pellet was carefully 
resuspended in 1 ml of PBS. Five hundred µl of the supernatant and 500 µl of the cell pellet 
suspension were tested in a hemolysis assay. Colony forming units (CFUs) were determined 
by spotting 20 µl of 10-fold dilutions (107 - 1014) of cell suspensions on Broth A agar plates 
and incubating the plates at 37°C for 4 - 5 days. 
The appearance of NADH oxidase activity in the supernatant fraction was used as an 
indicator of cell lysis. The NADH oxidase assay was performed as follows . Two hundred µl 
aliquots (0.4 - 0.6 mg per ml protein) was removed from the incubating mixture at 30 min 
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intervals for a total of 7 to 8 h, and the whole cells were removed by centrifugation as 
described above. The assay mixture contained 200 µl of supernatant, 100 µl of solution A (0.5 
M HEPES buffer-75 rnM KCI, pH 7.5), and 600 µl of H20 . The reaction was initiated by the 
addition of substrate ( 100 µl of 0.64 rnM ~-NADH) and the tubes were incubated at room 
temperature. The optical density at 340 nm was recorded with a UV 1604 Shimadzu spectro-
photometer by following the decrease in absorbance using the Time Scan Mode for 300 
seconds as described (144). A decrease in optical density indicated the presence of NADH 
oxidase. The slope of the curve is indicative of the enzyme concentration. 
Purification Schemes 
Preparative isoelectric focusing 
High resolution preparative isoelectric focusing using the Rotofor (BioRad Laboratories) 
was used in attempts to purify the sHL. The apparatus containing the 15 ml cell was assembled 
per manufacturer's instructions and the sample was loaded in a total volume of 40 ml. The 
sample was prepared by mixing 40 ml of diluted sHL with a carrier ampholyte (Ampholine 
3.5-9.5, Sigma catalog number A-4549) at a final concentration of 2% (v/v). Total protein was 
relatively low(:::; 0.5 mg) . Running conditions were as follows: the cell was focused for 4 hat 
1 lW constant power at 4°C. The initial voltage was 154V, and at equilibrium, the voltage rose 
to 400V where it remained constant. The anodic buffer was O. IM H3P04 and the cathodic 
buffer was O.lM NaOH. The gradient was harvested as twenty fractions, and their pH values 
measured. A 2.13 to 11.23 pH gradient was formed. 
The Rotofor fractions were dialyzed using Spectra/Par 2 dialysis tubing (Spectrum Medical 
Industries, Inc., Los Angeles, Calif.) against 100 volumes of lM NaCl for 1 to 1.5 hand then 
against PBS (pH 7.4) overnight at 4°C. After removal of ampholytes, aliquots were analyzed 
for the presence of HL activity using a blood agar plate assay. The presence of antigen in the 
harvested, dialyzed Rotofor fractions was determined by enzyme linked immunosorbent assay 
(ELISA) using monoclonal antibody 1D4G 12 shown previously to block M. pulmonis 
hemolytic activity (77). 
High performance liquid chromatography 
High pressure liquid chromatography (HPLC) was also used in attempts to purify the 
hemolysin. A reverse-phase analytical C-18 column (21mmx22 cm) (Vydac, Hesperia, 
Calif.) was used for most of the HPLC separations using a Waters 600E HPLC system. 
Before the sample was loaded, the column was equilibrated with 2 column volumes of 
degassed HPLC-grade water. After this step, the column was then equilibrated with 2 column 
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volumes of Buffer A (1 % TFA, trifluoroacetic acid). An elution gradient was then run 
repeatedly from 0-100% Buffer B (0.8% TFA in acetonitrile) until no more peaks eluted from 
the column. Five hundred µl of sHL was injected into the column, and the parameters for 
separation were as follows: Flow rate= 0.2 ml per min at a pressure of 700 psi; elution 
program: 0-5 min 100% Buffer A; 5-20 min 0-20% linear gradient Buffer B; 20-25 min 20-
45% linear gradient Buffer B; 25-45 min 100% Buffer A. Proteins were detected at a 
wavelength of 214 nm with a sensitivity of 1. 7 absorbance units full scale. 
A Bio-Gel SEC-30 XL (7.8 cm x 30 cm) column (Bio-Rad) was also used in the HPLC 
separations. This column was washed with 20% dimethylsulfoxide for 45 min at a flow rate of 
1 ml per min before use. The same procedure parameters and elution programs as above were 
used. Both analytical and preparative runs were performed. The preparative run flow rate was 
0.6 ml per min. PBS-lmM ~-mercaptoethanol-0.1 mM phenyl methyl sulfonyl fluoride 
(buffer A) and PBS-12% acetonitrile (buffer B) were used as the mobile phases. 
Proteins eluted from the C-18 reverse-phase and the Bio-Gel SEC-30 XL columns were 
collected by the peak detection method, dried with a Speed Vac concentrator (Savant 
Instruments, Inc., Farmingdale, N. Y.) and dissolved in 60 µl of PBS. Blood agar plates were 
used to detect hemolytic activity. The presence of the HL antigen was determined by both 
ELISA and immunoblots using the hemolysin-blocking monoclonal antibody 1D4G 12. The 
HPLC analysis was performed at the Iowa State University Protein Facility. 
Low pressure column chromatography 
In order to determine if hemolytic activity bound nonspecifically to various chromatography 
media, Sepharose (Sigma), Sephacryl S-200 (Pharmacia), and Sephadex G-200 (Sigma) were 
incubated with sHL and the remaining hemolytic activity in the supernatant fraction assayed. 
To accomplish this, the various media were rehydrated, washed several times with PBS and 
resuspended to 50% in PBS. One ml of sHL was placed into microfuge tubes and various 
amounts of the media (50, 100, 200, and 400 µl) were added to the sHL. These tubes were 
then rocked for 45 min at 4°C and then spun down slowly. Four hundred µl of the various 
supernatants were analyzed for remaining hemolytic activity using a standard assay. 
Supernatant not reacted with chromatography media was used as a control. In some studies, 5, 
10, or 20% glycerol (final concentration) was added to the sHL prior to the incubation with the 
chromatography media in attempts to prevent nonspecific adherence of the sHL activity. 
Gel filtration chromatography was performed using Sephadex G-200. To prepare samples 
for gel filtration, 100 mls of supernatant from soluble hemolysin preparations were 
concentrated to 5 mls by using Diaflo membranes (XM50; Arnicon, Beverly, Maine). Three 
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mls of the concentrated sample were applied to a 2.5 x 18 cm Sephadex G-200 column 
(Amicon, Beverly, Maine) at an operating temperature of 4°C. Samples had:::;_ 5 mg protein per 
ml. The eluting buffer was PBS. One and a half ml fractions were collected, and 400 µl of each 
fraction was assayed for activity at a final dilution of 1:6.25. Fractions containing hemolytic 
activity were referred to as partially-purified hemolysin (pHL). 
Electrophoresis 
Washed M. pulmonis was suspended in water to achieve a concentration of 2-5 mg protein 
per ml. s.HL, pHL, and heat-inactivated pHL were concentrated to approximately 250 µg 
protein per ml. Samples were prepared by heating at 100°C for 1-2 min in sodium dodecyl 
sulfate (SDS)-PAGE sample buffer (4% SDS-10% ~-mercaptoethanol-125 mM Tris-20% 
glycerol, pH 6.8), cooled, and then layered on the stacking gel. SDS-PAGE slab gel 
electrophoresis was performed by the method of Laemmli (94) using a 3% stacking layer (pH 
6.8) and a 10% resolving gel (pH 8.8). All gels were allowed to polymerize overnight at 4°C. 
A Bio-Rad model Protean II slab gel apparatus was used with a Bio-Rad model 3000xi power 
supply (Bio-Rad). Gels were electrophoresed for 3 to 4 hat 20 mAmps per slab gel. After 
electrophoresis, the gels were stained with an aqueous solution containing 0.025% (wt/vol) 
Coomassie blue (Bio-Rad)-50% (vol/vol) methanol-12% (vol/vol) acetic acid. Gels were 
destained in the same solution without Coomassie blue. 
For radioactive samples, gels were impregnated with 1 M sodium salicylate (Fisher, Itasca, 
Ill.) for 30 min to enhance the radiographic signals, and then dried under a vacuum using a 
Hoefer gel drying apparatus. Radiolabeled proteins were identified by exposing the radioactive 
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gels to preflashed X-Omate-AR film (Eastman Kodak Co., Rochester, N.Y.) for 3 to 6 weeks 
at -70°C. Molecular weights were calculated from known high range molecular weight standard 
markers (GibcoBRL). 
Similar procedures were followed for preparative native-PAGE gels except that all SDS in 
the buffers and solutions were excluded and the samples were not heated. Following 
electrophoresis on a 5% 3 mm slab gel, the upper half of the gel was placed on a blood agar 
plate for a maximum of 4 h until a zone of lysis was observed indicating the location of the 
hemolytic activity. This particular band, about 1.5 cm from top of gel, was excised and the 
hemolytic activity was electroeluted using a Centrilutor Microelectroelutor (Amicon) for 6 h at 
200 Vat 4°C. Nondenaturing lX Tray buffer (3 g Tris-14.5 g glycine per L) was used as the 
electroelution buffer. Centricon-50 concentrators (Amicon) were used to collect and concentrate 
the electroeluted protein(s). The electroeluted hemolytic activity from the native gel will be 
referred to as eHL. 
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Immunoblots 
Following electrophoresis for 3-4 h at 20 mAmp constant current, proteins were transferred 
to nitrocellulose (Midwest Scientific, St. Louis, Mo.) following the procedure of Towbin et. 
al. (206). A Hoofer model TE 42 Transphor apparatus with a model TE-50 power supply was 
used for this transfer process. The electrode buffer contained 25 rnM Tris-192 rnM glycine-
20% methanol (vol/vol), pH 8.3. A current of 1 Amp was applied for 2 h to insure efficient 
transfer of all proteins to the nitrocellulose. Cooling was maintained by running the apparatus 
at 4°C. 
Nitrocellulose blots were removed from the transfer apparatus, and unreacted protein 
binding sites were blocked by incubation of the nitrocellulose in 1 % gelatin (BioRad) for 2 h at 
room temperature. The blots were rinsed once with TS buffer and incubated at room 
temperature for 18 h with monoclonal antibody 3.3.10.2 (10 µg per ml) that blocks mitogenic 
activity of M. pulmonis (provided by Dr. Yehudith Naot, Technion-Israel Institute of 
Technology, Bat Galim, Haifa, Israel). Blots were washed once in TS buffer for 10 min, twice 
with TSN buffer (TS-0.05% Tween-20) for 20 min, and once again with TS buffer for 10 min 
to remove unbound antigen. The antigen-antibody complexes were detected by reacting the blot 
for 1.5 hat room temperature with goat antibody to rat IgG (whole molecule) conjugated to 
alkaline phosphatase (Cappel, Organon Teknika Corp., Westchester, Penn.) at a 1:1000 
dilution in TS buffer. The blot was washed twice with TS buffer for 15 min each, twice with 
TSN buffer for 20 min each, and once with TS buffer for 15 min. The blot was developed by 
using 0.03 g Napthol AS-MX phosphate (Sigma) plus 0.06 g Fast Red Tr (Sigma) dissolved 
in 40 ml of 20 rnM Tris, pH 7.5. 
For analysis of HPLC or Rotofor fractibns, 15 µl of each HPLC or Rotofor fraction was 
dried by vacuum (Savant) for 20 min to evaporate off the acetonitrile in the case of HPLC 
fractions or to concentrate the fractions. The pellets were the resuspended in 6 µl of PBS, and 
then 5 µl of each sample was dotted onto a nitrocellulose membrane and left to air dry. These 
blots were blocked with milk blocking buffer (PBS-5% Carnation instant milk-0.05% Tween-
20-0.2g Thimersol) for 1-2 h. Undiluted 1D4G12 Mab was incubated with each blot overnight 
at 4 °C. The same washing steps were then followed as described above. Horseradish 
peroxidase labeled goat anti-rat IgG (H+L) conjugate (Bio-Rad) was diluted 1: 1000 with TSN 
and placed on the blots for 75 min. The same washing and development steps were followed as 
described above. 
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Protein Sequencing 
The 10 µl of retentate from the electroelution process was separated on a 10% SDS-P AGE 
gel at 15 mA. This gel was soaked in sequencing transfer buffer [10 mM 3-[cyclohexylamino]-
1-propanesulfonic acid (CAPS)-10% methanol, pH 11.0] for 15-20 min to allow diffusion of 
the Tris-glycine buffer. The proteins were transferred to Immobilon-PSQ PVDF (Millipore 
Corp. , Bedford, Maine) for 2 hat 1 Amp. The PVDF membrane was stained with Coomassie 
blue for 2 min and then destained. The bands were excised, washed with HPLC grade water 
and loaded onto a pre-conditioned filter for sequence analysis. The N-terrninal sequence 
analysis was performed with an Applied Biosystems, Inc., Protein Sequencer Model 477 A 
equipped with an on-line PT A amino-acid analyzer model 120A. Repetitive Edman 
degradations were performed on the eHL sample using this automated system. The PTH amino 
acids were then passed through a reverse-phase Vydac C-18 (21mmx22 cm) HPLC column 
and detected at 270 nm. Their retention time was then compared with the PTH amino acid 
standards both visually and by computer data analysis programs. This N-terrninal sequencing 
was performed by the Iowa State University Protein Facility (Ames, Ia). 
Enzyme Linked Immunosorbent Assay (ELISA) 
ELISAs were performed as previously described (7 1). Rotofor and HPLC fractions were 
dried under vacuum (Savant) and resuspended in 50 µl of PBS. ELISA plates for the HPLC 
and Rotofor fractions were prepared by coating a 96-well serocluster 'U' vinyl plate (Costar, 
Cambridge, Maine) with 75 µl of coating buffer (0.1 M sodium carbonate, pH 9.6) and 25 µl 
of either HPLC or Rotofor sample to each well. These plates were allowed to incubate for 4 h 
at room temperature or at 37°C. The plates were washed 3 times with ELISA wash buffer 
(0.9% NaCl-0.05% Tween 20), waiting 10 min between each wash. The wells were then 
blocked for 1 hat room temperature with PBS-0.5% BSA. The wells were then washed 4 
times with ELISA wash buffer, and 100 µl of undiluted 1D4G 12 Mab was incubated in the 
wells overnight at 4 °C. Plates were washed three times with ELISA wash buffer prior to the 
addition of 100 µl of horseradish peroxidase labeled goat anti-rat IgG (H+L) conjugate (Bio-
Rad) per well at a 1 :3000 dilution in PBS-0.1 % BSA. The plates were incubated for 1 h at 
37°C, washed three times with ELISA wash buffer, and developed using TMB peroxidase 
substrate (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, Md.) according to the 
manufacturer's directions. ELISA plates were read at 450 nm using an automated microplate 
reader (BioTek, Model EL310, Winooski, Vt.). 
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Cell Culture 
The murine monocytic/macrophage cell lines 1774.Al and P388.Dl were obtained from 
American Type Culture Collection (Rockville, Md.). 1774.Al cells were grown in 37°C in 
Dulbecco' s minimum essential medium (Gibco Laboratories) supplemented with 4.5 mg D-
glucose-5% fetal bovine serum-5 ml of gentamicin (0.82% solution, Sigma)-5 ml of PKS 
(0.627% penicillin (Sigma)-1 % kanamycin (Sigma}-1 % streptomycin)-0.3 g L-glutamine, per 
liter. The 1774.Al cells were maintained as monolayers in petri dishes (Fisher brand #08-757-
13). Liquid policeman (PBS-0.2 g per liter EDTA) was used to harvest the adherent 1774.Al 
cells from the petri dish. 
P388.Dl cells were grown at 37°C in RPMI 1640 (Gibco Laboratories)-15% fetal bovine 
serum-5 ml of gentamicin-5 ml of PKS-0.3 g L-glutamine, per liter. This cell line was also 
maintained as monolayers in bacteriologic treated petri dishes and harvested using a disposable 
cell scraper (Fisher). All cell cultures were initially tested for mycoplasmal contamination using 
the Hoescht stain kit (Flow Laboratories, Inc., McLean, Va.). To keep a stock of all cell lines, 
they were frozen in their respective medium containing 15% dimethylsulfoxide (Fisher) in 
liquid nitrogen. 
Chemotaxis Assay 
Chemotaxis of 1774.Al cells was assayed in a 48-well micro-chemotaxis chamber 
(Neuroprobe, Bethesda, Md.) as previously described (64). 1774.Al cells were washed once 
in DMEM media and resuspended to 2.6x106 cells per ml in chemotaxis medium (Gay's 
Balanced Salt Solution (GBSS, Gibco Laboratories)-0.5% BSA) prior to use. The upper wells 
of the chamber were filled with 1774.Al cell suspensions (0.035 ml), and the bottom wells 
contained 0.025 ml of various concentrations of M. pulmonis pHL (0.1 - 50 µg protein per ml) 
obtained by purification through a G-200 Sephadex column as described above or human 
recombinant C5a (Sigma) at a concentration of 1 nM. The final dilutions of all attractants were 
prepared daily in chemotaxis medium. Chemotaxis medium and PBS served as negative control 
stimuli. Six replicates of each stimulus were placed in the bottom wells. The chamber was 
incubated for 3 hat 37°C in humidified 5% C02. The polycarbonate filter membrane 
(Nucleopore - 5.0 µm) was then removed, fixed, and stained. The migrated macrophages were 
counted with a lOOX objective. Two fields were counted per well, and the mean and standard 
deviation of triplicate wells was determined. 
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Blastogenesis Assay 
Mitogens 
Various concentrations of pHL (0.1 - 50 µg protein per ml) prepared as described above 
were tested for mitogenic activity. The final dilutions of all mitogens were prepared daily in 
RPMI 1640 (GIBC0)-25 mM HEPES-0.2% NaHC03 -2 mM L-glutamine. For some 
studies, the pHL was heated at 70°C for 1.5 hrs to abolish hemolytic activity. Heat inactivated 
pHL was tested at 5 and 0.1 µg protein per ml in the blastogenesis assay. As a positive control, 
M. pulmonis cell cultures were harvested in the late-log phase of growth by centrifugation for 
15 min at 8,000 x g at 4°C. The pellets were washed with PBS by centrifugation and then UV 
irradiated for 30 min. These nonviable suspensions were then sonicated on ice for 5 min to 
disrupt the membranes. The sonicate-was then aliquoted and stored at -70°C until use. Protein 
was determined by using the BioRad Assay as described above. Concentrations used for 
blastogenesis ranged from 0.125 - 20 µg per ml protein. LPS-endotoxin (K235 E. coli 
endotoxin; Sigma) was diluted to concentrations ranging from 0.1 to 10 µg per ml. 
Concanavalin A (ConA, Sigma) was diluted to 0.25 to 1 µg per ml. 
Lymphocytes 
Three- to 4-week-old C3H/HeJ and C3H/He0uJ mice were killed by asphyxiation. Their 
spleens were removed aseptically, minced, and pressed through a sterile metal screen (mesh 
size, 250 µm) into cold RPMI media (1 % fetal bovine serum). Red blood cells were lysed 
using a mixture of 90 ml of 0.2 M NH4Cl and 10 mls of 0.24 M Tris, pH 7 .2. Most of the 
macrophages were removed by adherence by placing the spleen cell suspensions in tissue-
cultured treated plates (Falcon #3003, Becton Dickinson) and incubating at 37°C for 2 hrs. The 
resulting lymphocytes were Washed twice and resuspended to a final concentration of 5x106 
cells per ml using RPMI media. 
Assay 
Immediately before use, the mitogens were prepared by diluting them to the appropriate 
protein concentrations listed above using RPMI 1640-25 mM HEPES-10% fetal calf serum, 
and 20 µg per ml gentamicin. 5x 105 spleen cells per well (0.1 ml volume) were cultured in a 
humidified atmosphere containing 95% air and 5% C02 for a total of 48 hrs in a 96-well flat-
bottomed micro titer plate (Costar, Cambridge, Maine) along with 0.1 ml of mi to gen giving a 
final volume of 0.2 ml per well. Controls included medium plus cells alone (negative control) 
and cells with M. pulmonis mitogen, LPS-endotoxin or ConA (positive controls). Twenty-four 
hours before harvest, 0.5 µCi of [3H]thymidine was added to each culture well. The cells were 
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collected onto glass fiber strips, and washed with distilled water using a PHD cell harvester 
(Cambridge Technology, Inc.). The strips were then air dried and counted using ScintiVerse 
(Fisher) scintillation cocktail in a Packard 1500 Tri-Carb liquid scintillation counter (Meriden, 
CT). All assays were run simultaneously in triplicate so that the results could be compared. 
Phagocytosis Assay 
Fluorescence labeling of E. coli 
Fluorescein-labeled E. coli were used as the physiological targets for phagocytosis. E. coli 
K-12 strain L929 was grown overnight in Luria-Bertoni media (172), washed by 
centrifugation, and the cells were resuspended in PBS at a concentration of 1.0 x 109 cells per 
ml. The cell suspension was heat treated by incubation at 60°C for 70 min, and the cells were 
washed with 1 ml of HBSS and then resuspended in 1 M NaHC03 to achieve a concentration 
of 5x106 cells per ml. Fluorescein isothiocynate (FITC) isomer-I (Sigma) was added to a final 
concentration of 0.3 µg per ml, the tube was covered in foil, and then incubated at 25°C on a 
rotator for 60 min. Bacteria were washed twice with 1 ml of HBSS and frozen at -20°C in 80% 
glycerol. The cells were thawed and washed one time the day of the experiment. Uniformity of 
staining was confirmed by flow cytometry. 
Assay 
The phagocytic assay was performed as follows. J774.Al and P388.D 1 mouse 
monocytic/macrophage cells were harvested, washed and resuspended to a final concentration 
of 2 x 105 cells per ml. Fifty µl of each cell suspension were injected into flow cytometer tubes 
(Falcon# 2002_. Becton Dickinson, Lincoln Park, N.J.) along with 67 µl of various 
concentrations of pHL (0.1 - 50 µg protein per ml). The tubes were kept in an ice-water bath 
for 15 min to allow cells and pHL to acclimate. Twenty µl of FITC-conjugated E. coli was then 
injected into each tube and vortexed. Except for the negative control maintained at 0°C for the 
duration of the experiment, the tubes were shifted to a 37°C water bath and incubated for 10- 12 
min. The tubes were removed immediately and placed in the ice-water bath to stop 
phagocytosis. One hundred µl of ice-cold quenching solution (Trypan blue, 4 mg per ml) was 
added to each tube, the tubes were vortexed and the cells were fixed by the addition of 2 ml of 
PBS-0.5% paraformaldehyde within 10 min. These tubes were vortexed and centrifuged at 
150 x g for 5 min. Supematants were removed leaving about 1 ml of fluid. Two ml of PBS-
0.1 % sodium azide was added to each tube, vortexed, and the tubes were centrifuged at 150 x 
g for 5 min. Supematants were again removed except for 1 ml. Two hundred µ l of PBS-0. 1 % 
paraformaldehyde was then added to each tube. Propidium iodide (Sigma) at a final 
46 
concentration of 50 µg per ml was added to all tubes just before cytometric analysis. All 
samples were analyzed by flow cytometry (Cell & Hybridoma Facility, Iowa State University, 
Ames, Ia.). Bacteria that were not engulfed by the macrophage cell lines were gated out from 
bacteria that were engulfed by differential intensities of red propidium iodide. Macrophages that 
did not engulf bacteria were distinguished from macrophages that did by assessing the different 
intensities of green florescence of FITC. 
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RESULTS AND DISCUSSION 
Kinetic Studies 
The initial studies undertaken were to determine the kinetics of release of sHL in order to 
maximize its production. By correlating loss of viability, cell lysis (appearance of NADH 
oxidase) and appearance of sHL in the culture supernatant it might also be possible to shed 
light on whether release of sHL was a normal physiological process of the organism or it 
resulted from degradation following cell death. This correlation was accomplished using a 
timed release assay as described above. By calculating total HL activity in the cell suspension 
prior to incubation with the amount released during incubation, it was possible to estimate the 
percentage of released activity by M. pulmonis whole cells in RPMI. Approximately 20% of 
the activity in whole cells was released into the supernatant during the incubation period. 
Figure 1 shows the release of sHL activity during incubation in RPMI media over time. 
Also shown is the viability of the cells (CFUs) and the remaining mHL in the cell pellet. A 
gradual release of sHL activity was observed for the first 5 h with a sharp increase at this time. 
Viability in the cell suspension was steady for about 3 h and then decreased during the next 4 h 
until little viability remained. The mycoplasma-associated mHL activity remained steady for 
about 3 h and then sharply decreased until a basal level was reached and maintained throughout 
the experiment. 
Aliquots were obtained every 30 min from the experiments above and the supematants 
measured for NADH oxidase activity. Figure 1 also shows the results of those experiments. 
There was no NADH oxidase activity released until 2 h when a sharp increase was observed 
(shown by the increase in the negativity of the slope). The correlation of NADH oxidase 
release with a decrease in cell viability indicated that cell lysis occurred immediately upon cell 
death during sHL preparation. This also suggested that hemolytic activity was not secreted 
continuously by the organism. Release of sHL may have been due to the loss of membrane 
potential upon cell death or it could have occurred following actual membrane rupture. Since it 
was not possible to separate cell death from cell lysis, further examination of this phenomenon 
was not possible at this time. 
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Figure 1. Correlation of hemolysin release with cell viability and lysis. Upper panel. Inverse 
correlation of sHL release with cell viability. Mycoplasma cell suspensions in RPMI buffer 
supplemented with 50 mM HEPES buffer (pH 7.5) were incubated at 37°C over the indicated 
time interval and samples taken at 30 min time points to measure cell viability, sHL activity 
released into the supernatant and mHL activity remaining in the cell membranes. The data are 
from a single experiment, but are indicative of the trend observed in at least three different 
experiments. Lower panel. Release of NADH oxidase during incubation of M. pulmonis in 
RPMI at 37°C. The assay is described in the Materials and Methods. Data represents the mean 
of three experiments. 
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Soluble Hemolysin Purification 
In order to gain a better understanding of the nature of the sHL, attempts were made to 
purify the activity and biochemically characterize the mycoplasmal components involved. 
Multiple purification approaches were attempted because of the unusual nature of the hemolytic 
activity and its requirement for BSA (125). It was absolutely essential to maintain activity 
during purification since it was not clear if Mab 1D4G 12 bound to a mycoplasmal component 
or inhibited hemolysis through a steric hindrance mechanism. In previous studies, it had not 
been possible to identify a specific mycoplasmal component using 1D4G 12 either by 
immunoblot or in immunoprecipitation assays (78). The Mab had some reactivity to BSA as 
determined by ELISA, but it was clear from these earlier studies that reaction with the sHL or 
cell associated activity was stronger than to BSA alone (78). Thus, there was no clear marker 
for mycoplasmal hemolytic components during purification other than its activity. It was not 
possible to use detergents to assist in the purification scheme since incubation of sHL with 1 % 
CHAPS detergent followed by dialysis to remove the detergent resulted in a loss of activity 
(78). Therefore, purification schemes had to use nondenatured proteins in the absence of even 
mild detergents. In the situations where denaturation was likely to occur, HPLC and 
preparative isoelectric focusing, fractions were assayed for hemolytic activity and were also 
monitored for positive responses to Mab 1D4G 12. 
Purification by HPLC 
Because of the high resolution available with HPLC, sHL purification was first attempted 
in this way. Initially, a reverse-phase C-18 column was used to separate sHL fractions as 
described in Materials and Methods. The proteins were allowed to separate for a total of 30 
min. Figure 2 shows the typical peaks that were detected with each run. The majority of the 
peaks appeared to be hydrophilic with a few appearing to be more hydrophobic. A size-
exclusion column HPLC column (Bio-Gel SEC-30 XL) was also used with a lower percentage 
of acetonitrile (12%) then was used with the C-18 reverse-phase column (Figure 2). This was 
done to determine if the acetonitrile used was interfering with or destroying the hemolytic 
activity of the sHL. The sample protein concentration for each HPLC run ranged from 200-400 
µg per ml. Proteins eluted from both columns were collected by the peak detection method. 
Concentrated protein fractions were dotted onto nitrocellulose membranes and analyzed for the 
presence of Mab-reactive antigens as well as analyzed for HL activity. These same protein 
fractions were also used to coat a 96-well ELISA plate. None of the fractions eluted from the 
HPLC columns had HL activity or showed immunoreactivity with Mab 1D4G 12. 
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Preparative isoelectric focusing 
Isoelectric focusing (IEF) is a high resolution technique capable of resolving proteins that 
differ in pl by fractions of a pH unit. Since HPLC failed to resolve hemolytic activity due to 
inactivation during separation, nondenaturing techniques were next attempted. Isoelectric 
focusing in the absence of detergents is a powerful technique to isolate proteins in their native 
conformations. The Rotofor preparative apparatus has a focusing chamber divided into 20 
compartments located between a cation exchanger (anode H3P04) and an anion exchanger 
(cathode NaOH). During a typical Rotofor run, the protein(s) is eletrophoresed through an 
established pH gradient which is rapidly formed during the early stages of electrophoresis by 
small, charged molecules or ampholytes. Proteins migrate in the electrical gradient based on 
their net charge until they reach the pH where their net charge is 0 where they focus. The 
voltage drops when the ampholytes are moving and then will gradually increase while the 
proteins are focusing. When all the proteins are focused the voltage becomes steady. 
As a control, ampholytes (2%) were mixed with sHL, dialyzed and tested for HL activity. 
Addition of ampholytes did not inactivate the hemolytic activity. Ten to twelve mls of sHL 
were then loaded on the 15 ml Rotofor cell. Twenty samples were collected with each run, and 
their protein concentrations were measured. The final pH range established for each run was 
1.72-11.97. All of the samples were dialyzed and tested for hemolytic activity on blood agar 
plates and the presence of Mab-reactive antigen by dotting the individual samples onto 
nitrocellulose or by coating an ELISA plate. Fractions 1 - 4 in the acidic portion of the gradient 
showed positive HL activity on blood agar, but were not recognized by the Mab. Only fraction 
10 in the neutral portion of the gradient gave a positive response with the Mab. 
These results demonstrate the limitations of this approach and the unavailability of adequate 
immunoreagents for the detection of purified sHL. The presence of even small amounts of 
ampholytes resulted in lysis of red cells on blood agar so it is not clear if fractions 1-4 actually 
contained active sHL or if residual amounts of ampholytes remained in the samples after 
dialysis. The protein concentration of the samples was too low to analyze by SDS-PAGE. 
Also, previous studies showed that a majority of the proteins from M. pulmonis focused in this 
region of the cell which would make it difficult to identify a specific mycoplasmal component 
associated with HL activity. Because of the lack of confidence in the technique, it was decided 
to attempt purification by other techniques. 
Gel filtration 
Preliminary studies were performed to determine which gel filtration chromatographic 
media would be best suited for purification of sHL, Sephacryl (spherical allyl dextran and 
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Figure 3. Effect of Sephacryl S-200 on sHL activity. sHL containing fractions were mixed 
with Sephacryl S-200 chromatography media and then examined for HL activity as described 
in the Materials and Methods. With increasing amounts of Sephacryl S-200, activity decreased 
indicating nonspecific adsorption to the chromatography media. Data are from one experiment. 
N,N'-methylene bisacrylamide), Sepharose (cross-linked agarose), or Sephadex (cross-linked 
dextran). Initial tests proved that sHL activity nonspecifically adsorbed to both Sephacryl S-
200 (Figure 3) and Sepharose (Figure 4). Even when the combination of sHL and glycerol 
were reacted with Sepharose/Sephacryl beads the hemolytic activity did not reach the levels of 
hemolytic units as when compared to the sHL alone (Figure 5). Sephadex G-200 beads seemed 
to be the only column-chromatography matrix that did not nonspecifically adsorb any of the 
sHL hemolytic activity. 
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Figure 4. Effect of Sepharose beads on sHL activity. sHL containing fractions were mixed 
with Sepharose chromatography media and then examined for HL activity as described in the 
Materials and Methods. Data are from one experiment. 
Concentrated sHL was loaded onto a Sephadex G-200 column as described in Materials 
and Methods. All hemolytic activity was detected in the fractions containing the void volume 
with an estimated size of 200 kDa or larger (Figure 6), suggesting that the sHL is either a large, 
multimeric complex or that the protein or complex is nonglobular in shape. When analyzed by 
SDS-PAGE, the pHL fraction gave a single prominent band with several smaller bands (Figure 
7). The combination of ultrafiltration followed by gel filtration lead to a partially-purified 
hemolytic preparation designated as pHL. 
Native-PAGE gel purification 
To further purify the pHL obtained by gel filtration chromatography, 2 mls of pHL was 
loaded onto a 5%, 3 mm, preparative native-PAGE gel. A prominent band of MRBC lysis 
(Figure 8) was identified by laying the gel on a blood agar plate to determine the location of the 
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Figure 5. Effect of glycerol on the nonspecific adsorption of sHL to Sephacryl S-200 
chromatography media. Increasing concentrations of glycerol (5, 10 or 20%) was added along 
with increasing amounts of Sephacryl S-200 beads to sHL containing fractions, incubated and 
the remaining HL activity assessed as described in the Materials and Methods. Data are from 
one experiment. 
hemolytic activity approximately 1.5 cm from the top of the gel. Initial lysis of the blood agar 
happened within 4 hours of incubation at 37°C but diffused quickly throughout the agar over 
time (data not shown). This zone of lysis corresponded directly with a single band seen on 
native gels of pHL when stained with Coomassie blue (Figure 9). When electroeluted, this 
band is referred to as eHL. When comparing the Coomassie stained protein patterns of sHL 
loaded onto a native gel and pHL loaded onto a native gel (Figure 9), multiple bands can be 
seen on the sHL gel and only one band on the pHL gel. These results also support the 
hypothesis that the sHL is a large, multimeric complex. 
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Figure 6. Profile of hemolytic activity from Sephadex G-200 column. Concentrated sHL 
supernatant was separated on a Sephadex G-200 column, and the fractions analyzed for 
hemolytic activity using the standard hemolytic assay. The arrow indicates the beginning of the 
void volume. Results are from a typical gel filtration experiment. 
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Figure 7. SDS-PAGE analysis of partially purified sHL fractions. A 10% SDS-PAGE 
resolving gel was used to separate hemolytic fractions at the various stages of purification. The 
gel was stained with Coomassie blue. Lane 1, M. pulmonis whole cell proteins; lane 2, sHL; 
lane 3, pHL; lane 4, eHL; lane 5, heat-treated pHL; lane 6, eHL fraction used for protein 
sequencing (from mini-gel) . Asterisks indicate bands sequenced. 
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Figure 8. Analysis of pHL on MRBC agar when separated by native-PAGE. The upper arrow 
(white) indicates the hemolytic activity associated with the top region of the native gel. The 
lower gray arrow shows activity that is sometimes observed after prolonged incubation of the 
gel on the MRBC agar. 
1 2 
Figure 9. Coomassie blue stained native PAGE gel of hemolytically active sHL and pHL 
fractions. Lane 1, sHL fraction; lane 2, pHL fraction. 
Protein sequencing 
SDS-PAGE analysis of the active band(s) electroeluted from native gels revealed that the 
pHL was a multi-protein complex which may still contain contaminating proteins (Figure 7). 
The proteins were transferred to PVDF membrane and three of these bands (indicated by 
arrows) were excised and sequenced by the Iowa State University Protein Facility. The 
prominent middle band gave a sequence of DTAK(S+S')EIAHRFKDCG. The upper band had 
several sequences present, suggesting either that proteolytic degradation had occumed or that 
there are several N-terrninal sequences possible for this peptide/protein. The most likely 
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sequence for the upper band was K?PKSEIAHR. The sequence for the lower band was not 
interpretable due to low protein concentration. Cycles with a "?" indicate that there seemed to 
be no major amino acid present for the cycle. This may indicate either a cysteine which cannot 
be detected unless it is pyridylethylated, a glycosylated amino acid, or a modified amino acid. 
BLASTP searches of the protein databases showed that the upper band had the highest 
homology (35%) with alpha 1-proteinase inhibitor. The middle band showed high homology 
(81 % ) to bovine serum albumin suggesting that this component is horse albumin derived from 
the serum component of the medium. 
From the results above, the best purification procedure for the M. pulmonis sHL involved a 
combination of methods. Ultracentifugation was used to remove the M. pulmonis membrane 
fraction followed by ultrafiltration to concentrate the sHL. Gel filtration of the concentrated 
material on Sephadex G-200 was then performed collecting the sHL in the void volume. The 
final purification step which still retained hemolytic activity was native-PAGE. Active fractions 
could be electroeluted from native gels and analyzed further, but the use of any procedure that 
disrupted the complex resulted in the loss of hemolytic activity. Figure 7 shows how the 
combination of these methods yielded a partially-purified sHL by comparing M. pulmonis 
whole cell proteins, sHL, pHL, and eHL (electroeluted HL from a native-PAGE gel). 
Radiolabeling Studies 
The results mentioned previously clearly show that sHL is a large complex and that serum 
albumin is a major constituent of that complex. This suggests that the hemolytic activity is 
composed at least partially of a serum contaminant, but other studies clearly show that a 
mycoplasmal component is also required for activity. In the initial studies identifying the M. 
pulmonis hemolysin, Minion and Goguen showed that trypsin treatment removed the hemolytic 
activity from the mycoplasmal cell surface (125). Since the assay is performed in 1 % BSA, 
trypsin treatment did not simply degrade the serum albumin of the membrane-associated 
complex. This could have been quickly replaced by the albumin in the assay buffer. Minion 
and Goguen also showed that following trypsin treatment, hemolytic activity could be 
regenerated, but only under conditions where protein synthesis was occurring (the protein 
synthesis inhibitor chloramphenicol prevented restoration of hemolytic activity) (125). Thus, a 
mycoplasmal protein component must be involved in the membrane-associated hemolysin 
activity. There is also the unanswered question of how the hemolytic complex is maintained in 
solution and whether a mycoplasmal protein component is involved in this structure or just in 
maintaining its membrane association during cell growth. These studies were undertaken in 
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order to determine if a mycoplasma protein or other macromolecule could be identified in the 
sHL complex through intrinsic radiolabeling procedures. 
358 methionine and cysteine metabolic radiolabeling 
The first radiolabeling experiments involved incorporation of Trans [35S] radiolabel 
(Amersham) metabolically into proteins via methionine or cysteine residues. This approach 
seemed reasonable since the mHL was proven to be sensitive to thiol-active compounds and 
oxidizing reagents suggesting a role for disulfide residues in the active site or in maintaining the 
complex's structure (79). Following radiolabeling, pHL was purified by gel filtration using 
disposable 0.8 x 4 cm columns (BioRad) and the void volume was analyzed by SDS-PAGE 
and autoradiography as described in the Materials and Methods. The results of this study are 
shown in Figure 10. 
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Figure 10. SDS-PAGE analysis of 35S-labeled whole cell protein, sHL and pHL fractions. 
Lane 1, whole cell protein (2 hour exposure); lane 2, sHL fraction (3 day exposure); lane 3, 
pHL fraction (3 day exposure). 
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14C amino acid radiolabeling 
In an attempt to improve the radiolabeling of the mycoplasma proteins by either 
increasing the specific activity of the labeling (all amino acids are radiolabeled as opposed to 
only methionine and cysteine) and potentially the number of proteins labeled (some 
mycoplasma proteins may not contain either methionine or cysteine ), M. pulmonis cultures 
were radiolabeled with a [14C] amino acids mixture. pHL fractions were then prepared from 
these radiolabeled cells using disposable columns and analyzed by SDS-PAGE as described in 
the Materials and Methods. The M. pulmonis 14C-labeled whole cell protein when compared 
with the M. pulmonis 35S-labeled whole cell protein, lane 1 in the [35S] autoradiograph (Figure 
10) showed more protein bands indicating that the labeling was more universal. The specificity 
of labeling was much lower, however, and it was not possible to identify specific proteins in 
either the sHL or pHL fractions radiolabeled with 14C (data not shown). 
32P Na2HP04 radiolabeling 
Protein modification by phosphorylation has only been identified very recently in 
mycoplasmas (212). Therefore, it was of interest to determine if the hemolytic complex also 
contained phosphorylated mycoplasmal proteins. [32P] Na2HP04 was used to radiolabel M. 
pulmonis cultures which should label both phosphorylated proteins and possibly some lipids as 
well. To increase labeling efficiency, phosphates were first removed from the media by dialysis 
against Tris buffer prior to radiolabeling. The organisms were radiolabeled as described in the 
Materials and Methods and sHL and pHL preparations obtained as described for 14C- and 35S-
labeled preparations above. To confirm the proteinaceous nature of the radiolabeled bands, 
portions of the preparations were subjected to trypsin digestion. These preparations, including 
the trypsin-digested material, were then analyzed by SDS-P AGE. Only the whole-cell pellet 
lane contained radiolabeled bands, mostly at the stacking/resolving layer interface; no radiolabel 
was detected in either the sHL or pHL lanes (data not shown). 
Biological Activities of pHL on Immune Effector Cells 
Studies were undertaken to further delineate the functional nature of this pHL activity. 
Following successful colonization of host tissues by invading microorganisms, interactions 
between mycoplasmas and the host immune system are initiated. Various cellular assays were 
performed to examine the biological effects of the hemolysin on chemotaxis, blastogenesis, and 
phagocytosis. 
61 
Chemotaxis 
A wide range of concentrations of pHL (0.1 to 50 µg/ml) were tested for their chemotactic 
potential for J774.Al mouse macrophages. The results of this study are shown in Figure 11. A 
strong chemotactic activity was observed with concentrations from 5 to 50 µg per ml of pHL. 
The 30 µg per ml concentration gave the strongest chemotactic dose response when compared 
to the positive control GBSS + 1 µg per ml C5a. A checkerboard analysis was then done to 
determine whether chemokinesis (increased random motility) contributed to the observed 
J774.Al chemotactic (directed migration) response. This was done by placing 10 µg per ml of 
pHL on both sides of the filter thus abolishing the concentration gradient of pHL. Since 
enhanced migration was not dependent upon a gradient of pHL (compare 10 pHL with 10 pHL 
(T&B), Figure 11), it appeared that pHL is both chemokinetic and chemotactic. This is not 
surprising since C5a, a well-known, potent chemoattractant, also shows chemokinetic 
properties. Heat inactivation decreased the chemotactic activity by approximately 50% which is 
in agreement with previous studies by Ross et al. (165). 
PBS 
GBSS 
GBSS+ 1C5a 
50 pHL 
30pHL 
20pHL 
10 pHL 
5pHL 
1 pHL 
0.1 pHL 
10 pHL (T&B) 
HT 10 pHL 
0 5 10 15 20 25 30 
Mean Number of Cells/12 Oil Immersion Fields 
Figure 11. Effect of pHL fractions on J774.Al migration. Data are expressed as the number of 
cells per 12 oil immersion fields (magnification, lOOX). Data represent mean± standard error 
of three experiments, 6 replicates per experiment. T &B, pHL in both top and bottom wells; 
HT, heat treated (70°C, 90 min). 
62 
Blastogenesis 
In vitro stimulation of C3H/HeOuJ mouse splenic lymphocytes with M. pulmonis lysate, 
pHL, and heat-inactivated pHL was determined by the uptake of [3H]thymidine. The 
blastogenic activity of these preparations, except for pHL, was found to be comparable in 
strength to those of ConA and LPS-endotoxin (Table 1). These results show that mouse 
splenic lymphocytes respond strongly to ConA, LPS-endotoxin (positive controls), and M. 
pulmonis lysate. In contrast, they were not significantly simulated by nondenatured pHL which 
was surprising due to the presence of potent mitogens in the M. pulmonis membrane. Once 
pHL was heat treated (70°C, 90 min), however, the in vitro proliferative response of mouse 
spleen cells to pHL was enhanced compared with the untreated pHL preparations. 
The effect of heat-treated pHL on mouse splenic lymphocyte responses to ConA and LPS-
endotoxin was also studied. Heat-treated pHL had no effect on LPS-endotoxin stimulation at 
the 0.1 and 10 µg per ml concentrations and only a slight effect at the 1 µg per ml concentration 
(Table 2). In contrast, heat-treated pHL (1 µg per ml) + ConA (0.5-1 µg per ml) showed an 
increase in proliferation in comparison to the ConA alone treatment. Heat-treated pHL at a 
concentration of 5 µg per ml had no effect on ConA stimulation suggesting that increased levels 
of heat-treated pHL adversely affected thymidine uptake in the presence of ConA. 
Various mycoplasmas differ not only in the lymphocyte subpopulation(s) they activate but 
also in their resistance to heat treatment. In most studies, the mitogenic activity of M. pulmonis 
was abolished upon heating (136, 137), although a recent report by Lapidot and Naot cites a 
heat stable mitogenic activity in M. pulmonis (103). Their studies discuss the use of Mab 
3.3.10.2 to study the M. pulmonis mitogen (103, 104). Therefore, it was of interest to 
determine whether this Mab reacted with sHL and pHL fractions and if heat treatment had an 
effect on this reactivity. These studies were performed by immunoblot using M. pulmonis 
lysate, sHL, pHL and heat treated pHL fractions resolved by 10% SDS-PAGE gels. The 
results of this study are shown in Figure 12. The Mab recognized two bands in the lysate 
sample, a band of approximately 97 kDa and a lower molecular weight band of approximately 
33 kDa. The sHL had multiple bands in the 75-95 kDa range; the upper band had the highest 
intensity probably indicating a higher concentration of this material. The pHL sample also had 
the multiple banding pattern of sHL, but with slightly different staining intensities; the lower 75 
kDa band had the same intensity as the upper 95 kDa band. Upon heat treatment, the multiple 
banding pattern was resolved to a single band of 75 kDa. These results suggest that sHL and 
pHL fractions contain a subset of the immunoreactive components of M. pulmonis recognized 
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Table 1. Mouse lymphocyte blastogenesis induced by various M. pulmonis preparationsa 
a 
b 
Mi to gen Thymidine 
derived from: Uptake 
(µg per ml) (cpm± SD)b 
lysate 
2.0 4143 ± 260 
1.0 7148 ± 1398 
0 .5 10874 ± 745 
0.25 15296 ± 1046 
0.125 11190 ± 936 
pHL 
5.0 1337 ± 296 
3.0 2105 ± 734 
2.0 1781 ± 550 
1.0 1446 ± 387 
0.5 1666 ± 909 
0 .1 1054 ± 339 
0.01 1940 ± 255 
Heat-treated pHL 
5.0 12139 ± 902 
1.0 6584 ± 1661 
ConA 
1.0 10348 ± 1150 
0.5 12598 ± 2138 
0.25 25111 ± 2846 
LPS 
10.0 17290 ± 2444 
1.0 10839 ± 946 
0.1 3137 ± 544 
RPMI 1658 ± 382 
C3H/OuJ mouse spleen cells (5xl05 cells per well) were cultured in the presence of 
various concentrations of M. pulmonis lysate, pHL, heat inactivated (HIA) pHL, 
ConA, and LPS-endotoxin. 
Results represent the mean± standard deviation (SD) of three independent experiments 
each performed in triplicate. 
by Mab 3.3.10.2. Lapidot et al. also suggest that the prolonged heat treatment (70°C, 90 min) 
of pHL had a substantial effect on the size of the complex components as determined by SDS-
PAGE (104). This could be due to changes in the conformation of the immunoreactive 
components or to their modification during heat treatment. It is important to note that Mab 
3.3.10.2-reactive components in pHL was lost upon further purification by native PAGE (data 
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not shown). This shows that the hemolytic activity of pHL has no relationship to the Mab 
3.3.10.2-reactive components of the partially purified material. 
Since heat treatment of pHL significantly altered its immunoreactivity to Mab 3.3.10.2, it 
was of interest to determine if a change in the overall size of the complex could be detected 
following heat treatment. pHL fractions, before and after heat treatment, were passed through 
10,000, 30,000 and 100,000 molecular weight cutoff ultrafilters and the retentate and filtrate 
were tested for blastogenic activity as described above. Blastogenic activity of the heat-treated 
pHL failed to pass through the 10,000 and 30,000 molecular weight cutoff filters, but passed 
partially though the 100,000 molecular weight cutoff filter (Table 3). This was in agreement 
with previous studies showing that sHL hemolytic activity could pass partially through a 
100,000 molecular weight cutoff filter (78). Thus, it appeared that heat treatment of pHL 
(70°C, 90 min) did not significantly alter the size of the complex. 
Table 2. Effects of heat-treated pHL on ConA and LPS-endotoxina 
Mi to gens 
(µg/ml) 
LPS-endotoxin 
10 
1 
0.1 
LPS +HT pHL (5) 
10 
1 
0 .1 
LPS +HT pHL (1) 
10 
1 
0.1 
ConA 
1 
0.5 
0.25 
ConA +HT pHL (5) 
1 
0 .5 
0.25 
ConA +HT pHL (1) 
1 
0.5 
0.25 
RPMI 
Thymidine 
Uptake 
(cpm±SD) 
15936 ± 968 
4750 ± 1365 
3173 ± 388 
11092 ± 80 
7832±1105 
5820 ± 539 
15556 ± 269 
9949 ± 291 
3574 ± 779 
9009 ± 1495 
12598 ± 2138 
24099 ±3082 
10440 ± 289 
12595 ± 511 
18666 ± 1296 
18720 ± 238 
23640 ±4060 
23031±1809 
1993 ± 248 
aResults are means of three independent experiments each performed in 
triplicate. HT, heat treated. 
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Figure 12. Immunoblot analysis of M. pulmonis lysate, sHL, pHL and heat-treated pHL using 
Mab 3.3.10.2. Each sample was treated at 100°C for 2 min in SDS-PAGE sample buffer. 
Heat-treated pHL was treated at 70°C for 90 prior to addition of sample buffer. Lane 1, M. 
pulmonis lysate; lane 2, sHL; lane 3, pHL; lane 4, heat-treated pHL; lane 5, eHL. Molecular 
weight standards are given in kilodaltons on the left. 
Table 3. Effect of ultrafiltration on heat-treated pHL blastogenic activity. 
Mol. Wt. Cutoff Size 100,000 30,000 10,000 
Retentate 6257 ± 1191 11550 ± 5871 13066 ± 2037 
Filtrate 7678 ± 1181 2105 ± 378 1990 ± 39 
Heat-treated pHL 
5.0 12139 ± 902 
1.0 6584 ± 1661 
RPMI 1658 ± 382 
aResults are means ± standard deviation of one experiment in triplicate. 
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Phagocytosis 
Previous studies of M. pulmonis interactions with alveolar macrophages suggested that 
these organisms contained a trypsin-sensitive anti-phagocytic factor on the cell surface (54). 
Therefore, it was of interest to determine if the trypsin-sensitive hemolytic activity (pHL) could 
serve this purpose. pHL was examined for its ability to stimulate phagocytic activity of 
1774.Al and P388.Dl cell lines. The results of these studies is shown Figure 13. The percent 
phagocytosis of either cell line was not affected by pHL at any concentration used. Thus, it 
appears that pHL is not related to the anti-phagocytic activity observed previously by Davis et 
al. (54). 
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Figure 13. Effect of pHL on phagocytic activity of 1774.Al and P388.Dl cell lines. Numbers 
represent µg of pHL. White bars are results with P388.D 1 cells, gray bars are results with 
1774.Al cells. Data represent means± standard error of three experiments, duplicates within 
each experiment. 
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CONCLUSIONS 
Based upon the results of these studies, the following conclusions have been made: 
1) Incubation of mycoplasma suspensions under conditions that inhibit cell division 
results in the release of soluble hemolytic activity (sHL). 
2) Appearance of hemolytic activity (sHL) in the cell suspension supernatant occurs after 5 
hours of incubation. 
3) The release of sHL correlates with cell death, probably occurs as a consequence of 
membrane rupture and is not a normal consequence of in vitro cell growth. 
4) The increase in NADH oxidase activity observed in the cell suspension supematants 
correlated directly with the loss of viability indicating that cell lysis occurs even in an 
isotonic buffer. 
5) sHL appeared to be a large complex because it was found in the void volume of a 
Sephadex G-200 column. By that criteria, the complex had a molecular size of 200 kDa 
or greater. Ultrafiltration data, however, indicated that the complex had a size of 
approximately 100 kDa. This suggests that the complex is not globular in shape, but 
may have a rod-like shape which could explain both observations. 
6) The main component of pHL appeared to be serum albumin, a requirement for 
hemolytic activity. 
7) Intrinsic radiolabeling demonstrated that mycoplasmal components were also 
incorporated into the hemolytic complex, but it was not possible to identify a specific 
compon~nt as'sociated with the hemolytic activity. 
8) The anti-rnitogenic Mab 3.3.10.2 recognized several bands in the sHL, pHL and heat-
treated pHL fractions. This reactivity was lost upon further purification by native 
PAGE demonstrating that Mab 3.3.10.2-reactive components had no relevance to the 
hemolytic activity. 
9) The complex had the property of nonspecific adherence to various surfaces including 
two chromatography media, Sepharose and Sephacryl. 
10) The pHL showed strong chemotactic and chemokinetic activity for J774.Al 
macrophages which approached the activity of C5a. The concentration of 30 µg per ml 
was the most active of the concentrations tested. 
11) Although it enhanced the migratory activity of macrophages, pHL had no effect on their 
phagocytic activity. 
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12) Untreated pHL had no effect on mouse splenic lymphocytes, but heat-treated pHL 
(70°C, 90 min) was a potent blastogenic factor. Since heat-treated pHL (1 µg per ml) 
enhanced the ConA response (0.5-1 µg per ml), the blastogenic effect of pHL appears 
to reside with mouse T cells. This rnitogenic activity is different from previously 
reported activities. 
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